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SUMMARY 
 
Chronic myeloid leukaemia (CML) is a disorder of the haematopoietic stem cell 
(HSC) characterised by the presence of a characteristic chromosomal 
translocation which forms the Philadelphia chromosome. The disease is caused by 
BCR-ABL, a constitutively active tyrosine kinase and the protein product of the 
oncogene BCR-ABL which forms as a result of the chromosomal translocation. 
 
The current recommended treatment for the majority of patients with chronic 
phase (CP) CML is the tyrosine kinase inhibitor (TKI) imatinib mesylate (IM). There 
is accumulating evidence that the majority of patients respond to this drug and 
achieve the therapeutic milestone of a complete cytogenetic response (CCyR). 
However TKI induce a state of minimal residual disease (MRD) in the majority with 
BCR-ABL transcripts detectable in peripheral blood (PB). The source of MRD in IM 
treated patients is presumed to be leukaemic HSC. These cells are relatively 
insensitive to all TKI. Furthermore the development of TKI-resistant BCR-ABL 
mutations is a cause of primary and secondary treatment failure. In particular the 
T315I BCR-ABL mutation is resistant to all available TKI and there is concern that 
selection pressure may result in this mutation becoming more prevalent. 
 
The proteasome is an attractive target for cancer therapy and there has been 
expansion of the clinical use of bortezomib, to date the only licensed proteasome 
inhibitor (PI). There is published evidence that BCR-ABL expression is associated 
with increased proteasome activity, that primitive CML cells express higher levels 
of BCR-ABL than their more mature progeny and that BCR-ABL+ cell lines are 
susceptible to proteasome inhibition (1-4). We have extended this work to 
demonstrate that CD34 enriched samples taken at diagnosis from patients with CP 
CML have reduced proliferation and undergo apoptosis with bortezomib exposure. 
This effect was replicated in 7 different patient samples and the drug was 
consistent in its effect. The antiproliferative and apoptotic effects were associated 
with an accumulation of polyubiquitinated proteins consistent with inhibition of the 
proteasome. Despite these effects, bortezomib did not appear to influence BCR-
ABL kinase activity as evident by pCrkl detection by Western blot. The 
concentration required to reduce the viable cell count by 50% (LD50) in CD34+ 
CML cells was comparable to that quoted previously for CML blast crisis (BC) cell 
lines (10-15 and 32nM at 48 hours (h) (1, 3)), purified human multiple myeloma 
 16 
cells from bone marrow (BM) (2.5-30nM at 48h (5)) and CD34 enriched human 
acute myeloid leukaemia (AML) cells (5-10nM at 7 days (d) (6)). Pharmacokinetic 
and pharmacodynamic data from treated patients would suggest that such 
concentrations are clinically achievable. 
 
We used an established technique to isolate the CD34+38- cells from patient 
samples. This population contains the primitive and quiescent HSC which are 
resistant to current therapies. We demonstrate for the first time that these cells are 
sensitive to the apoptotic effects of bortezomib at comparable concentrations to 
those achieved in vivo. These data are in concordance with published 
observations of the sensitivity of CD34+38- AML cells to the PI MG132 (7). We 
extended the work to track cells through division using carboxy-fluorescein 
diacetate succinimidyl diester (CFSE) staining and flow cytometry. We 
demonstrate that proliferation of CD34+ CML cells is significantly affected by 
bortezomib exposure and at high concentrations the few surviving cells remain 
undivided. Recovery calculations were made and at concentrations of bortezomib 
comparable to the LD50 there is a depletion of CD34+ cells from all stages of 
division including the undivided state. This contrasts with dasatinib exposure, 
which may result in the accumulation of undivided cells. 
 
Clinical trials with bortezomib have shown that reversible haematological toxicity 
(in particular severe thrombocytopaenia) is very common. We show that normal 
CD34+38- cells are susceptible to the apoptotic effects of bortezomib with LD50 
values only slightly higher than those of the CML HSC. We could find no published 
data of the effects of bortezomib in this specific cell population. Other groups have 
used, as a control population, non-malignant CD34+ enriched cells (LD50 11.3nM 
by assays of colony formation and <20nM by proliferation assays (6, 8)) and 
lymphocytes from PB (~5% apoptosis with 50nM by annexin-V staining (9)). The 
toxicity we demonstrate is concerning, however the reversible nature of the severe 
cytopaenias seen in patients may reflect an improved recovery of this population 
relative to malignant cells. It is noted that in Phase I dose escalation studies using 
more intensive regimes, the dose-limiting toxicity was haematological (10).  
 
An established technique to ameliorate toxicity of chemotherapy is to use drug 
combinations. We speculated that TKI may provide additional benefits to 
bortezomib treatment in view of the presence of residual BCR-ABL kinase activity 
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in PI treated cells. We demonstrate that bortezomib and dasatinib are synergistic 
in inducing cell death using concentrations of both drugs that may be achieved in 
vivo.  
 
We have also shown that bortezomib consistently induces apoptosis in cell lines 
expressing BCR-ABL mutations including T315I. This is associated with a 
reduction in chymotrypsin-like (CT-L) enzyme activity consistent with bortezomib 
effect. Interestingly we show for the first time that the proteasome subunit activity 
may vary amongst different BCR-ABL mutations and this is not thought to be due 
to different BCR-ABL protein levels.  
 
In conclusion bortezomib is antiproliferative and induces apoptosis in CML CD34+ 
cells including the CD34+38- fraction, believed to be the source of residual 
disease in TKI treated patients. Potential toxicities associated with this drug may 
be bypassed by synergistic interactions with dasatinib. Bortezomib is also effective 
in the presence of TKI resistant BCR-ABL mutations. With these two key findings 
we believe that PI should play a future role in the treatment of patients failing 
current therapies. 
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1 INTRODUCTION 
 
1.1 Classification 
CML is classified by the World Health Organisation as a myeloproliferative 
disorder, one member of a group of conditions including essential 
thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis. The 
myeloproliferative diseases are clonal disorders of the HSC characterised by 
abnormal myeloid (i.e. granulocyte, erythroid and megakaryocytic) proliferation. 
CML (also termed chronic myelogenous or granulocytic leukaemia) has a 
characteristic molecular biology and is now more appropriately considered as a 
distinct entity. 
 
1.2 Epidemiology 
CML has an estimated incidence of 1-2 new cases per 100000 population per year 
(y) (11). Figures from Scotland (1980-2005) are in concordance with this, with an 
average of 60 new cases/y from a population of approximately 5 million. The 
incidence has changed little in Scotland over the decade 1994-2004.  The median 
age affected is between 65y and 69y with a slight male predominance (cancer 
statistics accessed in January 2009 from the National Statistics section of the 
Information Services Division (ISD) Scotland, www.isdscotland.org and general 
population statistics from the General Register Office for Scotland, www.gro-
scotland.gov.uk). 
 
1.3 Clinical Manifestations 
CML evolves through 3 clinical phases.  The CP is characterised by leucocytosis 
and hepatosplenomegaly developing as a consequence of increased 
granulopoeisis and leukaemic infiltration.  At diagnosis the majority of patients are 
in CP and are asymptomatic. The disease will then progress either directly to BC 
or through an intermediate accelerated phase (AP).  AP is characterised by an 
increased number of primitive precursors in BM or PB. BC occurs when there is a 
failure of maturation of the malignant precursors, often accompanied by additional 
cytogenetic abnormalities and resulting in a disease resembling AML or acute 
lymphoblastic leukaemia (ALL).  There have been significant advances in the 
treatment of CP disease and progression to advanced stage is seen less 
frequently. However, when it occurs the prognosis is poor and the median survival 
measured in months (m) (11).   
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1.4 Pathogenesis 
CML arises as a consequence of a rare mutational event resulting in a reciprocal 
translocation between the long arms of chromosomes 9 and 22. The shortened 
chromosome 22 formed by this translocation is the Philadelphia chromosome 
(Ph+), named after the city in which it was discovered. The translocation creates 
the chimeric oncogene BCR-ABL with the protein product BCR-ABL, a tyrosine 
kinase with constitutive activity. BCR-ABL is responsible for the pathogenesis of 
CML as demonstrated by the transforming ability of BCR-ABL expression in cell 
lines and mice (12, 13).  This oncoprotein is therefore the focus for investigations 
into the pathogenesis of CML and has provided a tangible target for therapy. 
 
1.5 BCR-ABL and the malignant phenotype 
BCR-ABL confers a survival advantage on cells by influencing signalling pathways 
which control proliferation and apoptosis. It may be the advantage is relatively 
subtle: BCR-ABL is detectable, transiently it is presumed, in a “normal” population 
(14, 15); and exposure to known triggers of CML, such as ionising radiation, have 
a disease latency of years (16). An outline of the signalling pathways affected by 
BCR-ABL provides insight into the mechanism by which the malignant phenotype 
may be established. 
 
1.5.1 Intracellular signalling pathways 
Enzyme-linked receptors provide a mechanism for cell signalling and play a role in 
proliferation, differentiation, apoptosis and migration. Of the different classes of 
enzyme-linked receptors, the most common have tyrosine kinase function 
(receptor tyrosine kinase, RTK) and include the RAS and phosphatidylinositol 3-
kinase (PI3K) pathways (Figure 1.1). Others are associated with proteins which 
have tyrosine kinase activity and include the Janus kinase (JAK) pathways (Figure 
1.2).  
 
1.5.1.1. RAS and PI3K pathways 
In outline, RTK binding results in autophosphorylation and so provides 
phosphotyrosine docking sites for intracellular proteins containing SRC-homology-
2 (SH2) domains. Once bound, SH2-containing proteins may interact with other 
tyrosine phosphorylated proteins. This interaction may take place via additional 
binding domains, such as SH3 domains, on the signalling molecule.  
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RAS is a guanosine triphosphate (GTP)-binding protein associated with RTK 
(Figure 1.1). Through activation of RAS and downstream serine-threonine kinases 
the activity of gene regulatory proteins are influenced - including those responsible 
for cell proliferation. It has been demonstrated previously that BCR-ABL interacts 
directly with growth factor receptor bound-2 (GRB-2) and activates the RAS 
pathway (17). Furthermore, inhibition of tyrosine kinase activity abrogates the 
activation of RAS (18). Consistent with this, BCR-ABL+ cell lines have detectable 
levels of RAF activity and colony growth of CML cells appears to depend on this 
(19).  
 
A further relevant and important signalling pathway activated through RTK 
involves PI3K activation (Figure 1.1). Through PI3K there is promotion of cell 
growth and survival through a pathway involving AKT (a serine-threonine kinase) 
with downstream targets which include mammalian target of rapamycin (mTOR). 
BCR-ABL interacts with and promotes activity of PI3K. Inhibition of PI3K in BCR-
ABL+ cells will inhibit growth (20). AKT activity is also essential in BCR-ABL 
mediated leukaemogenesis seen in vitro as colony growth and in vivo in mouse 
transplantation models (21). 
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Figure 1.1. RAS activation. RAS exists in active (GTP-bound – activated by GEF) 
and inactive (GDP-bound – inactivated by GAP). RAS is linked to the RTK by 
adaptor proteins including GRB-2. GRB-2 contains an SH2 domain (so binding to 
the RTK) and two SH3 domains. Through the SH3 domains GRB-2 is associated 
with SOS proteins which function as a GEF (so activating RAS). Activated RAS 
recruits and activates MAPKKK (=RAF) which then activates MAPKK (=MEK) 
activating MAPK (=ERK). ERK then influences the activity of gene regulatory 
proteins and through this cellular proliferation. PI3K activation. PI3K catalyses the 
generation of PIP2 and PIP3. These phospholipids contain docking sites for PH-
domain containing signalling proteins, enabling them to come in close proximity 
and so interact. An important example is PIP3 dependent activation of AKT, a 
process requiring phosphorylation of AKT by PDK1. Once activated AKT 
phosphorylates many target proteins including mTOR, which serve to promote cell 
growth and survival. 
Abbreviations in figure and legend– RAS pathway Guanosine triphosphate (GTP), 
Guanine nucleotide exchange factors (GEF), guanosine diphosphate (GDP), 
GTPase-activating proteins (GAP), receptor tyrosine kinase (RTK), growth factor 
receptor bound-2 (GRB-2), SRC-homology-3 (SH3), Son of Sevenless (SOS), 
mitogen activated protein kinase (MAPK), MAPK kinase (MAPKK), MAPKK kinase 
(MAPKKK), MAPK/ERK kinase (MEK), extracellular signal-related kinase (ERK) 
PI3K pathway Phosphatidylinositol 3-kinase (PI3K), phosphatidylinositol (3,4) 
diphosphate (PI(3,4)P2), phosphatidylinositol (3,4) triphosphate (PI(3,4,5)P3), 
pleckstrin homology (PH), 3-phosphoinositide-dependent protein kinase 1 (PDK1), 
mammalian target of rapamycin (mTOR). 
 
SOS 
GRB2 GTP GDP 
ERK 
MEK 
RAF 
RAS RAS 
Cellular proliferation 
Receptor 
tyrosine 
kinase 
 
 
Cell membrane 
Intracellular space 
Akt 
mTOR 
AKT 
PDK1 
PI3K 
PIP2 PIP3 
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1.5.1.2. JAK pathway 
The Janus kinase (JAK) family are cytoplasmic tyrosine kinases activated 
following cytokine receptor binding (Figure 1.2). This activation proceeds through 
signal transducers and activators of transcription (STAT) proteins which directly 
regulate gene activity promoting expression of anti-apoptotic factors (including 
BCL-XL). STAT overexpression is seen in cancers including CML and it has been 
shown in BCR-ABL+ cells that STAT1/3/5 are phosphorylated and constitutively 
active (22-24). This activity may be abrogated by TKI (25, 26). 
 
 
Figure 1.2 Activation of JAK results in activation of STAT proteins which directly 
regulate gene activity. STAT proteins contain an SH2 domain and may also be 
activated independently of JAK. 
Abbreviations - Janus family kinase (JAK), signal transducers and activators of 
transcription (STAT), proteins. 
 
1.6 The haematopoietic stem cell in CML 
 
1.6.1 The leukaemic stem cell 
The normal HSC performs characteristic stem cell functions of self-renewal, 
allowing perpetuation of haemopoiesis and the production of differentiated 
progeny, initially as lineage-restricted progenitors through to mature blood cells. 
These functions are regulated by soluble cytokines and interactions between cells 
and stroma. The term “HSC” describes a relatively heterogenous group of cells 
with varying self-renewal capacity and propensity to generate different lineages. In 
CML there is a population of leukaemic HSC characterised by the presence of the 
Philadelphia chromosome and BCR-ABL oncogene (Ph+HSC). Consistent with 
Ph+HSC precursors, BCR-ABL containing cells of all lineages (excluding mature T 
cells) are seen by different techniques, including: conventional cytogenetics (27, 
28); glucose-6-phosphate dehydrogenase clonality (29); and fluorescence in-situ 
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Intracellular space Receptor 
STAT 
JAK 
Anti-apoptotic factors 
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hybridisation analysis (FISH) following fluorescence activated cell sorting (FACS) 
(30). The clinical consequence of the HSC basis is reflected in the manifestation of 
a broad range of disease subtypes associated with progression to BC CML.   
 
The majority of normal HSC are quiescent, stabilised in cell cycle resting stage 
G0, with infrequent cell cycles every 1-3m (31, 32). The turnover of the Ph+HSC is 
deregulated with the majority of cells in cycle at any given time. These cells show 
autocrine IL-3 and granulocyte-colony stimulating factor (G-CSF) production and 
so may proliferate in the absence of exogenous growth factors (33). Despite this, it 
is estimated that approximately 0.5% of Ph+HSC remain quiescent and represent 
a more primitive Ph+HSC sub-population. These quiescent cells are capable of 
generating BCR-ABL+ progeny in immunocompromised (non-obese diabetic, 
severe combined immunodeficiency, NOD/SCID) mice, indicating that in vivo the 
quiescent state is reversible (34). In common with CML, both AML and ALL are 
thought to have a leukaemic HSC basis with cells identified capable of 
reconstituting disease following engraftment in NOD/SCID mice (35, 36). The 
diseased HSC is a key target for therapy - these cells may act as a reservoir of 
disease and through quiescence, self-renewal and increased proliferative potential 
be resistant to conventional therapy and remain capable of reconstituting the 
disease state. 
 
Isolation of HSC relies on defining particular morphological and molecular 
characteristics. A combination of functional assays - to exploit HSC self-renewal 
and multi-lineage differentiation - and FACS have identified particular molecular 
characteristics of HSC in the normal and leukaemic state (Table 1.1). Colony 
formation is a functional assay. By this technique, cells are cultured in conditions 
to encourage proliferation and differentiation. The number of colonies formed will 
correlate to the number of colony-forming units (CFU) and hence indicate HSC 
number and function. A long term culture-initiating cell (LTC-IC) assay is a 
modification of this technique. Here a sample of cells containing primitive HSC is 
maintained for 5-8 weeks in culture on an established, irradiated, supportive 
stromal cell layer. The cells are then harvested and cultured in conditions to 
encourage colony formation. The formation of colonies will correlate to the 
persistence of primitive HSC throughout long-term culture. FACS when combined 
with functional assays has enabled identification of molecular characteristics 
particular to primitive HSC.  
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Table 1.1. Characterisation of leukaemia initiating cells 
Cell 
type 
Molecular characterisation Proof of stem cell 
nature 
Reference 
normal CD34+38- Single-sorted cells give 
rise to sequential plated 
colonies 
(37) 
normal CD34+38-33- LTC-IC (38) 
AML CD34+38-HLA-DR-CD71- 
(most cells capable of LTC-IC 
were CD34+38-) 
LTC-IC 
NOD/SCID mice 
leukaemia initiating cells 
(39) 
AML CD34+38- SCID mice leukaemia 
initiating cells 
(35) 
AML CD34+38-Hoechst 3342-* CFU 
LTC-IC 
NOD/SCID leukaemia 
initiating cells 
(40) 
CML CD34+38- NOD/SCID mice 
leukaemia initiating cells 
(41) 
Normal cells are those from healthy donors. *Stem cells are believed to be 
particularly efficient at effluxing the dyes Hoechst 33342 and Rhodamine (termed 
“side population” due to appearance on FACS). Colony-forming units (CFU) and 
long term culture-initiating cell (LTC-IC) assays. 
 
The selected studies seen in Table 1.1 demonstrate that selection of CD34+38- 
cells will contain cells with the capacity to self renew and form multi-lineage 
colonies and so have key HSC characteristics. Furthermore, a high proportion of 
CD34+38- cells are in G0 and have a high proliferative potential (as measured by 
response to in vitro stimulation with growth factors) (42). This population may 
therefore have a role in studies to monitor therapeutic effects on the more primitive 
HSC. 
 
1.6.2 Advanced phase disease and self-renewal capacity 
CP disease is associated with myeloid lineage leucocytosis and this reflects the 
capacity of the Ph+HSC to differentiate to mature progeny. More advanced phases 
of the disease resemble acute leukaemia and are associated with accumulation of 
poorly differentiated cells. This is the consequence of a cumulative effect of 
different genetic insults to the Ph+HSC. These include BCR-ABL mediated 
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deficiencies in DNA repair, genomic surveillance, loss of tumour suppressor 
function and telomere shorting (reviewed (43)). Of interest is recent speculation 
that progression to advanced stages may be associated with the gain of self-
renewal function in granulocyte-macrophage progenitor (GMP) cells. GMP are 
differentiated from HSC and would not normally have the capacity for self-renewal. 
However, a population of GMP cells selected from BC CML by FACS were 
capable of initiating leukaemia in mice (44) and BCR-ABL+ mouse GMP cells were 
capable of expanding in vitro (45). In both examples GMP self-renewal capacity 
was associated with activation of the β-catenin, a component of the WNT 
signalling pathway. 
 
1.7 Current CML therapy 
 
1.7.1 Imatinib 
The current recommended first line therapy for patients with CP CML is IM 
(Glivec®, Novartis Pharma, Basel, Switzerland) (46), a rationally designed TKI 
which gained a UK license in 2001. IM underwent successful phase 1 dose-
escalation studies (47, 48) and phase 2 trials (49) in patients with CML. This 
culminated in the phase 3 International Randomized study of Interferon and 
STI571 (IRIS) trial. In this untreated, newly-diagnosed patients with CP CML were 
randomised to receive either IM 400mg or interferon-alpha combined with low 
dose cytosine arabinoside (IFNα + Ara-C). The results showed IM as superior 
when considering haematological (HR) and cytogenetic responses (CyR), 
tolerability, or the likelihood of disease progression (50, 51). Table 1.2 outlines 
accepted response criteria and definitions for CML clinical trials. Recent results of 
front line IM therapy for CP CML show complete HR (CHR) in 97% and CCyR in 
82% (best observed responses). Disease progression was low but detectable in 0-
2.8% patients/y (52). Other multi-centre experiences with IM have been published. 
De Lavallade et al. analysed response to IM in 204 patients with newly diagnosed 
CP CML and showed a cumulative 83% incidence of CCyR at 5y (by intention to 
treat analysis) (53). Lower CCyR rates (51% at 2y) have also been reported in a 
smaller population-based study (54). However, despite impressive responses it is 
accepted that two key problems with IM remain – disease persistence and IM 
resistance. 
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Table 1.2 CML disease response definitions 
Haematological response Cytogenetic response† Molecular response‡ 
Complete* 
   Plt <450x109/L 
   WC <10x109/L 
   normal differential 
   spleen not palpable 
Complete 
Partial 
Minor 
Minimal 
None 
Ph+0% 
Ph+1-35%  
Ph+36-65% 
Ph+66-95% 
Ph+>95%  
Complete 
Major 
Undetectable 
<0.10% 
*Peripheral blood platelet count (Plt) and white cell count (WC) with normal 
differential implying a lack of immature granulocytes and <5% basophils. †Ph+ as 
% of total metaphases (at least 20) examined in bone marrow. ‡BCR-ABL to 
control gene ratio. Undetectable levels depend on sensitivity of assay. A major 
response may also be defined as a 3 log reduction from baseline. 
 
1.7.1.1 CML persistence despite imatinib therapy 
IM induces a state of MRD rather than cure. There is clinical evidence for this: the 
number sustaining a CCyR (66%) is far fewer than the number achieving this; 
BCR-ABL transcripts remain detectable in the majority of patients (55); and 
patients who discontinue IM are likely to suffer recrudescence of disease despite 
apparent disease control (56-59).  
 
The source of MRD may be the Ph+HSC. This theory originates from a number of 
in vitro and in vivo studies. Graham et al cultured CD34+ enriched fresh 
leukapheresis products, taken at diagnosis from 5 patients, in the presence or 
absence of IM. Although IM induced death in dividing cells, there remained a 
population of viable, quiescent BCR-ABL+ CD34+ cells, surviving despite 
exposure to concentrations of IM higher than would be expected in treated 
patients. IM was also antiproliferative, with an increased proportion of cells found 
in the undivided state in the presence of IM and growth factors, as compared to 
when growth factors alone were present (60). Similar conclusions  were reached 
by an independent group (Bhatia et al.) who used CFC and LTC-IC assays with 
primitive (CD34+38-) cells from patients newly diagnosed with CML (61). In 
addition, quiescent BCR-ABL+ CD34+ cells are insensitive to the effects of Ara-C, 
lonafarnib (farnesyl transferase inhibitor), LY294002 (PI3K inhibitor), 17-
allylamino-17-demethoxygeldanamycin (17-AAG, a heat shock protein (HSP) 90 
inhibitor) and arsenic, agents which cause apoptosis in the dividing cell population 
(62, 63). The clinical significance was confirmed by further work with CD34+ 
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selected BM samples taken from 15 IM treated patients with a CCyR.  Despite a 
confirmed response to IM in all, CFU and LTC-IC assays demonstrated that 
functional BCR-ABL+ progenitor cells remained. In addition, there was an 
increased frequency of BCR-ABL+ cells within the CD34+ cell fraction when 
compared to total BM mononuclear cells (MNC), indicating an enrichment of 
leukaemic cells within this population, consistent with earlier in vitro work (64). 
This work has been extended and presented recently. It has been shown that 
BCR-ABL+ primitive (CD34+38-) HSC are present in patients with CP CML in 
CCyR who have been treated with IM for 5y. Furthermore the BCR-ABL levels in 
this sub-population do not appear to decline during this time (65). The reversibility 
of the quiescent state which is consistent with Ph+HSC persistence has been 
demonstrated in a mouse model of CML. BM cells taken from mice with a CML-
like disease, which were treated with and had responded to IM, were transplanted 
into irradiated recipients - all of which then developed disease (66).  
 
1.7.1.2 Imatinib resistance mechanisms 
Response criteria are used to define primary IM resistance and include a failure to 
achieve at least a partial CyR (PCyR) after 12m or a CCyR by 18m therapy (50). 
IRIS trial data show that 16% and 24% respectively do not achieve these targets. 
De Lavallade et al. showed a failure to achieve at least PCyR at 12m in 39% and 
Lucas et al. failure to achieve CCyR by 18m in 51% of treated newly diagnosed 
patients (53, 54). Secondary IM-resistance is indicated by a loss of previously 
achieved response and will affect approximately 16% of newly diagnosed patients 
in the first 3y of treatment (51). BCR-ABL kinase domain mutations and drug 
transport are considered important resistance mechanisms, though other 
mechanisms have been described, such as amplification of the BCR-ABL 
oncogene (seen in 6% of those with IM resistance (67)). 
 
1.7.1.2.1 BCR-ABL mutations 
Mutations of the BCR-ABL kinase domain are seen in 35-45% patients resistant to 
IM and so have generated particular interest as a cause for treatment failure (67-
70). BCR-ABL mutations are more prevalent in advanced disease stages than in 
early CP and in the majority of patients (57-89%) are associated with acquired IM 
resistance (70, 71). Furthermore the detection of mutations may precede the 
development of resistance and is predictive of relapse. There is also evidence that 
BCR-ABL mutations may be seen in patients prior to initiation of IM therapy and so 
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may be a cause of primary resistance (72). Different mutations vary in their 
susceptibility to TKI as demonstrated by inhibition of proliferation of transfected 
BCR-ABL+Ba/F3 cell lines (Table 1.3). Of particular scientific significance is the 
T315I mutation. This is a phosphate-binding loop mutation found in all stages of 
CML and is associated with BCR-ABL resistance to all currently available TKI. The 
clinical significance is the subject of some debate. An analysis of 27 patients with 
T315I demonstrated that the 2y-survival (87% in CP patients) was similar to that of 
patients with no/other mutations (73). However disease phase is a well recognised 
indicator of prognosis and at the time of detection with T315I the majority of 
patients are in AP or BC (74).  
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Table 1.3 Comparative cellular proliferation assays of tyrosine kinase inhibitor 
treated BCR-ABL+Ba/F3 transfectants 
Imatinib Nilotinib Dasatinib  
IC50 
(nmol/L) 
Fold 
change 
IC50 
(nmol/L) 
Fold 
change 
IC50 
(nmol/L) 
Fold 
change 
       
T315I >6400 >25 >2000 >154 >200 >250 
Y253H >6400 >25 450 35 1.3 2 
E255V >6400 >25 430 33 11.0 14 
E255K 5200 20 200 15 5.6 7 
Y253F 3475 13 125 10 1.4 2 
M244V 2000 8 38 3 1.3 2 
F359V 1825 7 175 13 2.2 3 
V379I 1630 6 51 4 0.8 1 
Q252H 1325 5 70 5 3.4 4 
G250E 1350 5 48 4 1.8 2 
F317L 1050 4 50 4 7.4 9 
L387M 1000 4 49 4 2.0 3 
M351T 880 3 15 1.2 1.1 1.4 
H396P 850 3 41 3 0.6 0.8 
F311L 480 4 23 2 1.3 2 
       
WT  260 1 13 1 0.80. 1 
       
Table adapted from reference (75). Cellular proliferation assessed at 72h drug 
incubation by a methane-thiosulfonate based assay. Fold change refers to wild 
type (WT) i.e. p210 BCR-ABL. Those mutants seen more commonly (85% of 
mutations) are highlighted (█) (70). Rows highlighted (█) are those mutants 
available to use in this project. 
 
1.7.1.2.2 Resistance through mechanisms other than BCR-ABL mutation 
 
1.7.1.2.2.1 Drug transport - Efflux 
The ATP-binding cassette (ABC) transporter family form a large group of 
transmembrane proteins involved in many metabolic processes with the capacity 
to transport a variety of different substrates.  There are 7 subfamilies (ABCA 
through to ABCG).  Expression of these genes can be seen in normal and 
malignant cells.  Members of the ABC family are important in the mechanism of 
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multidrug resistance (MDR) (reviewed in (76)).  MDR is the simultaneous 
development of resistance to more than one therapeutic agent and can affect 
drugs with different mechanisms of action. Important genes encoding ABC 
transporters associated with MDR include: ABCB1, encoding P-glycoprotein (Pgp), 
also known as MDR1; ABCC1 with the protein product MRP1; and ABCG2 which 
is also named mitoxantrone-resistance protein or breast cancer resistance protein. 
Of these transporters ABCB1 and ABCG2 have been studied in CML, in particular 
for their role in IM transport.  ABCC1 appears to play a less significant role and will 
not be discussed further (77). 
 
1.7.1.2.2.1.1 P-glycoprotein 
The importance of Pgp in a variety of tumour types has been established 
(reviewed in (76)) with the contribution to drug resistance in CML under 
investigation. BCR-ABL+ cell lines may acquire resistance through increased 
expression of Pgp if cultured in vitro in titrated concentrations of IM. This 
resistance may then be overcome through selective inhibition of this transporter 
using verapamil (78, 79).  However these results have not directly translated in the 
clinical setting. Though Pgp inhibitors appeared to restore IM sensitivity in vitro to 
CML cells taken from the BM of 6 patients with IM-resistant BC CML – there was 
no evidence found for altered Pgp expression (79).  However, Galimberti et al 
demonstrated that expression levels of ABCB1 in 33 IM treated patients 
distinguished those patients who progressed to advanced phases of the disease 
(80).   
 
It may be that expression of Pgp is a crucial mechanism of IM resistance in a 
select group of patients; alternatively it may be one contributing factor influencing 
others. A novel approach targeting Pgp efflux as a presumed mechanism of IM 
resistance involves use of the HSP90 inhibitor 17-AAG. This compound disrupts 
the complex formed between HSP90 and BCR-ABL resulting in increased 
proteasomal degradation of BCR-ABL. 17-AAG has also been shown to inhibit 
Pgp activity, as shown by Rhodamine-123 efflux. This effect was demonstrated by 
Radujkovic et al. who also demonstrated synergy between IM and 17-AAG. This 
was seen in 2 IM-resistant cell lines, when the effects of reducing BCR-ABL levels 
and activity and apoptosis induction were considered. Synergism was not 
apparent in the IM-sensitive cell lines used for comparison. There was an additive 
effect on colony formation by PB MNC samples from 3 IM-sensitive patients in BC. 
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It was concluded that diminished Pgp activity may provide a mechanism for 
increasing intracellular concentrations of IM and so overcome IM resistance (81). 
This work is consistent with that of others, where evidence for an additive effect 
between 17-AAG and IM in BCR-ABL+ cell lines and CD34+ selected patient 
samples has been demonstrated. However, the quiescent Ph+HSC population are 
not sensitive to this combination (62). 
 
1.7.1.2.2.1.2 ABCG2 
ABCG2 is highly expressed in normal HSC though is downregulated with 
maturation. The function of high ABCG2 expression is not clear though it may 
provide a mechanism for drug resistance. IM interacts with ABCG2 and initial 
studies in BCR-ABL+ cell lines suggested that IM was a substrate for this 
transporter (82).  More recent work on patient samples showed that in common 
with normal HSC, Ph+HSC express ABCG2 at high levels.  IM inhibits the function 
of the transporter in Ph+HSC, shown by the accumulation of ABCG2 substrates 
(BODIPY-prazosin) and radiolabelled mitoxantrone.  Co-exposure of an inhibitor of 
ABCG2 (fumitremorgin C) did not enhance the effect of IM on BODIPY-prazosin 
accumulation, or alter the intracellular accumulation of radiolabelled IM.  This led 
to the conclusion that IM is an inhibitor of ABCG2 and not a substrate (83).  
Overexpression of this transporter should not therefore affect intracellular 
concentrations of IM or mediate resistance to this drug. Similar results were 
obtained by another group (84). Others have utilised BC CML and transfected cell 
lines and suggested that high levels of ABCG2 expression do mediate resistance 
to IM - though interpretation is complicated by evidence of IM induced 
downregulation of ABCG2 expression (85). The true answer to the question of 
ABCG2 involvement is of significance as this transporter may serve as a future 
target for drug and antibody therapy.   
 
1.7.1.2.2.2 Drug transport - Uptake 
IM is transported actively into cells by the human organic cation transporter 1 
(hOCT1). This protein is a member of the solute carrier superfamily and organic 
cation transporter (OCT) subfamily. Treatment of CP CML samples with OCT-1 
inhibitors (prazosin and procainamide) affects intracellular uptake and retention of 
IM (86).  Furthermore, the concentration of IM retained within the cell correlates 
with kinase inhibition (derived from Crkl phosphorylation).  This is of relevance 
clinically as the sensitivity of BCR-ABL kinase inhibition to IM correlates with 
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clinical outcome at 12 months (87). These results may not be translated directly to 
other TKI as nilotinib does not appear to be transported by OCT-1, presumably 
due to structural differences.  
 
1.7.2 Second-generation TKI 
 
1.7.2.1 Dasatinib 
Dasatinib (Sprycel®, Bristol-Myers Squibb, New York, USA) was approved in 2007 
for treatment of patients in Scotland with CP CML resistant to or intolerant of IM 
(www.scottishmedicines.org.uk). Dasatinib is one member of a family of dual ABL- 
and SRC-family kinase (SFK) inhibitors. SFK (in particular LYN and HCK) are 
downstream targets of BCR-ABL. However in IM-resistant patient samples and cell 
lines it has been shown that SFK may be active despite BCR-ABL inhibition and 
so support cell survival (88). Dasatinib binds the ATP-binding site of ABL in the 
inactive or active conformation – IM binds and stabilises only the inactive 
formation (89). In addition, dasatinib more potently inhibits BCR-ABL kinase 
activity than IM and effectively inhibits cell growth of cell lines expressing IM-
resistant BCR-ABL mutations. However, it is not effective against the T315I 
mutation (90).  
 
Clinical data from trials of dasatinib have been published. For those with CP CML 
and IM-resistance or intolerance best observed responses were 91% (CHR) and 
49% (CCyR). Of interest is that 74% of these patients were IM-resistant and 40% 
had a confirmed BCR-ABL mutation (91). Recent extended follow-up from this trial 
has been presented and responses appear durable with 86% maintaining a CCyR 
once achieved (92). However, as with IM, BCR-ABL transcripts remain detectable 
in 37-56% of patients at 2y (93). Responses are also gained in patients with 
advanced stage CML. The phase 2 AP trial achieved a 24% CCyR in IM intolerant 
or resistant patients with responses seen in patients with a range of BCR-ABL 
mutations. However, as predicted by in vitro data, patients with T315I (or F317L) 
failed to respond (94).  
 
1.7.2.2 Nilotinib 
Nilotinib (Tasigna, AMN107, Novartis Pharma, Basel, Switzerland) was approved 
in 2008 for treatment of patients in Scotland with CP CML resistant to or intolerant 
of IM (www.scottishmedicines.org.uk). Nilotinib is a TKI designed on the molecular 
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framework of IM. Analysis of the crystal structure of nilotinib-ABL complexes show 
that like IM, the drug binds to the inactive conformation of ABL though with subtle 
alterations in structure allowing a better topographical fit. Pre-clinical data 
confirmed the in vitro efficacy of this drug in IM-sensitive and resistant cell lines 
with complementary in vivo data from a murine CML model (95). Clinical trials in 
CP CML with IM-intolerance or resistance have been published and show 74% 
and 31% achieve a CHR or CCyR respectively (96) (updated to 77 and 42% with 
2y follow-up (97)). Responses appear durable with 84% of those with either CCyR 
or MCyR maintaining this. 42% of these patients had BCR-ABL mutations, 
however those with particular mutations including T315I, Y253F and E255V failed 
to respond. Few responses are seen in advanced phases of the disease, with 26% 
or 16% achieving a CHR or CCyR respectively (98).  
 
1.7.2.3 Front line use of second generation tyrosine kinase inhibitors 
Early phase 2 trial data suggests that use of the more potent TKI as first-line 
therapy may achieve more rapid response than IM. The rationale for this is based 
on analysis of the IRIS trial data which demonstrated that achievement of 
particular milestones – in particular CCyR at 12m and major molecular response 
(MMolR) at 18m – are associated with a low risk of disease progression (51). 
However despite impressive early responses (96/98% achieving CCyR with 
nilotinib/dasatinib) disease eradication is not achieved with detectable BCR-ABL 
transcripts in the majority (99, 100).  
 
1.7.2.4 Tyrosine kinase inhibitors in combination 
There is no significant cross resistance between nilotinib and dasatinib, with 
significant responses seen in a published series of patients with disease refractory 
to both IM and nilotinib therapy.  Cytogenetic responses were seen in 31% of 
these patients, though the durability of response is not clear with limited follow up 
data so far available (101). Therefore there may be benefits to be gained from the 
combination of IM with either dasatinib or nilotinib as all 3 drugs appear to 
predispose to the development of different BCR-ABL mutation profiles (102).  
Synergism of IM and nilotinib has been demonstrated in a variety of cell lines and 
a murine model of CML, however predictably the T315I mutation remained 
resistant (103)   
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1.7.2.5 Second generation tyrosine kinase inhibitors and the stem cell 
It is clear that currently available TKI are unable to treat CML where particular 
BCR-ABL mutations are found. There is also concern that the quiescent Ph+HSC 
population are insensitive to these drugs. It has been demonstrated in vitro using 
dasatinib that despite potent inhibition of BCR-ABL activity (using Crkl 
phosphorylation as a marker), a quiescent population of primitive Ph+HSC persist 
– despite the confirmed absence of BCR-ABL mutations (4). In a similar series of 
experiments tracking division of CD34+ CML cells in the presence of nilotinib, it 
was seen that quiescent Ph+HSC persist and may accumulate relative to 
untreated cells which will tend to divide and differentiate (104). 
 
1.8 The need for new approaches 
Within the leukaemic HSC population evidence is presented for a population of 
cells which are relatively insensitive to current TKI and characterised by phenotype 
(CD34+38-) and quiescence. This population will serve to sustain MRD, despite 
apparent adequate response to therapy. Patients will therefore remain on drug 
indefinitely for fear of disease recrudescence, and so with long-term therapy there 
is the theoretical risk that selection of resistant mutations (such as T315I) will 
occur. However it is accepted that longer term data from the IRIS trial supports the 
stance that MRD in the majority is of no consequence as once significant 
responses (MMolR) are obtained they appear durable with very few patients 
suffering disease progression. The only “curative” option remains haemopoietic 
stem cell transplantation, a procedure limited in application by donor availability 
and the toxicity of conditioning regimes. The success of TKI has led to a significant 
reduction in the popularity of transplantation for CML and it is now an option 
reserved in most UK centres for those with advanced stage disease (105).   
 
A number of different strategies are being adopted to improve the treatment of 
CML and these are outlined in Table 1.4 and have been reviewed (106). This 
introduction will focus on proteasome inhibition as a therapeutic strategy to target 
CML. 
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Table 1.4  Strategies to target imatinib resistance and disease persistence. 
Target mechanism examples reference 
    
BCR-ABL    
Activity newer tyrosine kinase 
inhibitors 
dasatinib, 
nilotinib 
Reviewed here 
Stability histone deacetylase 
inhibitors 
LBH-589 (107) 
 heat shock protein 90 
inhibitors 
geldanamycin 
17-AAG 
(107-110) 
enhance IM effects increased IM dose  (111-114) 
 combination of IM with 
IFN-A 
SPIRIT trial (115) 
 G-CSF scheduling GIMI trial (116) 
 drug efflux inhibition verapamil (79, 81, 117, 
118) 
BCR-ABL location nuclear trapping leptomycin B (119, 120) 
    
alternative targets    
 proteasome inhibitors bortezomib Reviewed here 
 farnesyl transferase 
inhibitors 
lonafarnib, 
BMS-214662 
(121) 
 protein kinase C bryostatin (122) 
 reactive oxygen species 
generation 
adaphostin (123, 124) 
 hypusination inhibitors ciclopirox (125) 
 aurora kinase inhibitors MK-0457 (126-128) 
    
 
 
1.9 The proteasome 
The proteasome is an intracellular organelle which functions as a targeted 
mechanism for protein degradation. Through this it plays a vital role in cellular 
processes such as cell cycling, adhesion, proliferation and apoptosis – all of which 
may be deregulated in cancer. An outline of the mechanism of proteasome 
function is illustrated in Figure 1.3. 
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Figure 1.3 An illustration of proteasome activity.  
TNFα (tumour necrosis factor-alpha) and IFNγ (interferon-gamma). 
 
The 26S proteasome is formed from a 20S core with two 19S regulatory cap units. 
Proteins are targeted for proteasomal degradation by the attachment of ubiquitin - 
this process following a series of catalytic reactions. Ubiquitin activating enzyme 
(E1) first binds to and activates ubiquitin, which is then transferred to one of a 
group of ubiquitin conjugating enzymes (E2). Ubiquitin protein-ligase enzymes 
(E3) then catalyse the binding of E2-bound ubiquitin to the target protein. Through 
multiple reactions a polyubiquitin tag is formed on the substrate which enables 
recognition by a proteasome cap unit. There are around 1000 different E3 ubiquitin 
ligases in the human genome and this step provides substrate specificity to the 
process. Furthermore, deregulation of E3 ubiquitin ligase activity is seen in human 
cancer (129). Following recognition by the cap unit, the ubiquitinated substrate is 
presented to the catalytic sites within the 20S core. The core comprises 4 stacked 
rings. Each ring is divided into 7α (α-ring) or 7β (β-ring) subunits.  The α-rings are 
associated with the cap units and act as gated channels.  Catalytic activity occurs 
on the β-rings as 3 peptidase activities (CT-L, tryptic (T-L) and postglutamyl 
peptide hydrolytic (PG)) and each activity is associated with a specific beta subunit 
(β5, β2 and β1 respectively) (reviewed in (130)).   
 
The substrate specificity of the β subunits is modified following stimulation with 
interferon-gamma or tumour necrosis factor-alpha and the designation of the 
subunits becomes β1i, β2i and β5i – the proteasome is then an 
immunoproteasome. This functional change enhances the ability of the cell to 
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present antigenic peptides via MHC class I.  There is some evidence that the 
immunoproteasome activity may predominate in certain types of haematological 
malignancy (131).  This change may be of significance when the measurement of 
proteasome activity is considered. 
 
1.9.1 Measuring proteasome activity 
Proteasome activity is conventionally measured by the turnover of fluorescent 
substrates for the 3 catalytic sites and results are expressed as released 
fluorescence units. Though widely adopted, it is recognised that there are 
limitations to this technique: cell lysis prior to analysis is required and it is not 
known how this will interfere with proteasome activity; immunoproteasome activity 
is not assessed by this method; and large numbers of cells (>1x107) are required. 
More recently, methods have been established using labelled compounds which 
act as PI and probe specific subunit activities in cell lysates (131) or live cells 
(132). This permits more detailed analysis of both proteasome and 
immunoproteasome activity using relatively small cell numbers. However, these 
are not commercially available. Activity may also be determined by indirect 
methods such as effects on pathways shown to be intimately associated with the 
proteasome for example the NFkB/IkB axis.  
 
1.9.2 Proteasome inhibitors and cancer 
Cancer cell lines have abnormally high levels of proteasome activity and 
expression (133) and have been shown to be relatively more sensitive to the 
effects of PI than their non-malignant counterparts. The first proteasome inhibitor 
to enter clinical trials was bortezomib (Velcade®, Janssen-Cilag International NV, 
Beerse, Belgium) and this remains the only PI approved for clinical use. It was 
licensed for use in Scotland in 2004 for patients with multiple myeloma who have 
received at least two prior therapies and who are refractory to alternative licensed 
treatments (www.scottishmedicines.org.uk). In addition bortezomib was licensed in 
the USA in 2006 for second-line use in patients with mantle cell lymphoma 
(www.fda.gov) and may be used in this disease in the UK within the context of a 
clinical trial (www.cancerhelp.org.uk). In the setting of two phase 1 clinical trials 
including Australia, Estonia and USA, NPI-0052 is a new PI under investigation for 
treatment of advanced malignancy including multiple myeloma. Carfilzomib (PR-
171) is a further PI which has shown evidence for efficacy in multiple myeloma and 
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mantle cell lymphoma and which is available for use in these conditions in open 
clinical trials. (National Cancer Institute, www.cancer.gov). 
 
1.9.3 Bortezomib 
In 1999 the National Cancer Institute tested a selection of related boronic acid 
derivative PI for activity in a variety of cancer cell lines. Of these, bortezomib 
(formally PS-341) demonstrated particular efficacy based on potency of 
proteasome inhibition (using fluorescence-based assays) and ability to inhibit 
cancer cell growth. The prostate cancer cell line PC-3 was selected from this initial 
study for more detailed investigation. It was shown in vitro that the concentration 
required to kill 50% of PC-3 cells at 48 hours (h) was 20nM. This compound also 
inhibited growth of tumours in mice when used at a concentration of 1.0mg/kg with 
comparable and detectable levels of radiolabelled drug in the PB and BM (134). 
The activity of bortezomib is relatively selective for CT-L activity and this has been 
confirmed by fluorometric and subunit probe-based assays (131). Laboratory and 
clinical investigations have been extended by many other groups using tumour 
models and cell samples from patients with haematological and solid organ 
malignancies. It is from these studies that a mechanism of action has been 
proposed and pharmacodynamic and pharmacokinetic information has been 
established. 
 
1.9.4 Proposed mechanism of proteasome inhibitors 
The proteasome is found in all eukaryotic cells, both malignant and non-malignant. 
A PI must therefore exploit a difference in activity and/or reliance of the cell upon 
that activity if it is to be selective. The state of cancer is generally accepted to 
involve an imbalance between those factors driving proliferation and those 
promoting apoptosis. It is likely that PI “tilt the scales” from cell survival to 
apoptosis in malignant cells by a number if ways. A complete mechanism of action 
is not yet known fully and may vary between different cell types utilising abnormal 
proteasome activity in different ways. 
 
1.9.4.1 The NFkB/IkB axis 
NFkB is a transcription factor that serves to support cell survival. This is achieved 
by promoting expression of anti-apoptotic genes as well as those influencing 
inflammation, proliferation and differentiation. Regulation of NFkB activity is well 
described and is illustrated in Figure 1.4. NFkB exists as a cytoplasmic form 
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bound to an inhibitory molecule IkB. The principal pathway leading to NFkB 
activation is the phosphorylation of IkB by IkB kinase (IKK). IkB is ubiquitinated 
and degraded by the proteasome. NFkB may then enter the nucleus and bind to a 
specific consensus site within DNA. Furthermore, IkB transcription is activated by 
NFkB leading to loss of NFkB from the nucleus and enabling negative 
autoregulation of the pathway (reviewed in (135)). The structure of the proteins 
involved is more complex than has been illustrated.  ‘NFkB’ is commonly used to 
describe a family of proteins which form homo- and heterodimers, the most well 
characterised form being p50/p65. The family of anchorin-domain containing 
inhibitory molecules binding NFkB and preventing nuclear translocation (termed 
‘IkB’ in Figure 1.4) include IkBα, IkBβ, IkBγ, IkBαε, bcl-3, p105 and p100. IKK 
consists of IKKα, IKKβ, and IKKγ (together referred to as NFkB essential 
modulator subunits).   
 
 
Figure 1.4 An illustration of the NFkB/IkB axis 
 
When the role of this pathway in proliferation, apoptosis and inflammation is 
considered, it is not surprising that constitutive NFkB activity has been 
demonstrated in many malignancies, including CML (136-138). Relevant to CML is 
the finding that NFkB is required for tumour development and primary BM cell 
transformation by BCR-ABL+ cell lines (17)  NFkB activation may occur 
downstream of BCR-ABL with suggested mechanisms involving BCR-ABL 
activation of serine-threonine kinases such as PKD2 (mediating activity through 
the IKK pathway) (137) and MEKK (139).  BCR-ABL may also increase the 
degradation of IkB through an undefined mechanism independent of IKK (138).  . 
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There is evidence for constitutive activation of NFkB in samples from patients with 
CML. PB and BM were taken from 17 patients with CML (15 CP, 2 myeloid BC) 
and analysed by electrophoretic mobility shift assays (EMSA) a standard 
measurement of nuclear NFkB activity. In both BC (but not in CP) a significant 
increase in activity was seen in comparison to healthy controls (140).  These 
findings were confirmed in a separate study analysing PB from 8 patients with 
CML BC by EMSA. Here the activity was unaffected by exposure of patients to IM, 
which is surprising when considering the evidence for BCR-ABL mediated NFkB 
activation (138).   
 
1.9.4.2 Bortezomib and the cell cycle 
The cell cycle is a regulated and ordered process of growth and division. It is 
conventionally divided into 4 sequential phases: G1, a synthetic phase; S phase, 
during which DNA duplication occurs; G2, a second synthetic phase; and M 
phase, during which the cell undergoes mitosis. The progression through these 
phases is controlled by cyclin dependent kinases (CDK), which are expressed and 
degraded at various points of the cell cycle. Cyclins are regulatory proteins which 
form a complex with CDK and are necessary for kinase activity. An illustration of 
the cell cycle is shown (Figure 1.5) demonstrating the function of various cyclin-
CDK complexes. 
 
 
Figure 1.5 An illustration of the role of the cyclin - cyclin dependent kinase (CDK) 
complex (white text boxes) and CDK inhibitors (blue text boxes) in cell cycle 
progression through 4 key phases (grey text boxes) with corresponding check-
points (black bars). 
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The retinoblastoma protein is (pRb) is of key importance for cell cycle initiation. 
pRb associates with E2F family of transcription factors and inhibits their activity. 
Phosphorylation of pRb leads to dissociation of the pRb-E2F complex. This 
phosphorylation is mediated by cyclin-CDK complexes (cyclin D–CDK3, cyclin D-
CDK6 and cyclin E-CDK2). E2F transcription factors which have been released 
from inhibitory binding, promote the expression of genes necessary for 
progression from G1 to S phase. Transition through S phase requires the 
repression of E2F activity and this involves Cyclin A–CDK2 and CDK1. The 
phosphorylation inhibits the DNA binding of the E2F. Transition through G2 into M 
phase requires the activity of cyclin B–CDK1 complexes. A further level of control, 
in particular during the G1 and S phase, is provided by the cyclin dependent 
kinase inhibitors (CDKi). There are two families of CDKi - the Cip/Kip family 
(p21cip1/waf1, p57kip2 and p27kip1) which inhibit the kinase activities of cyclin D-, E-, 
A- and B-CDK complexes, and the INK4 family which inhibit cyclin D-CDK4 and 
CDK6 complexes (141). Cell cycle transition is therefore mediated through loss of 
CDKi activity permitting progression and increased activity resulting in growth 
arrest. This may be illustrated by studies where p27kip1 was over-expressed in 
human cells with consequent G1 arrest (142).   
 
CDKi and the Cip/Kip family in particular are frequently deregulated in human 
malignancies and may be of prognostic value (143). It has been shown that BCR-
ABL+ cell lines have reduced levels of p27kip1 and this appears to be partially 
regulated by proteasomal degradation. A suggested mechanism involves BCR-
ABL regulated expression of SKP2 - this then influences ubiquitination (as part of 
a multiple component complex with E3 ubiquitin ligase activity) and hence 
proteasomal degradation of the p27kip1. It has recently been shown in cell lines that 
BCR-ABL induces phosphorylation of p27kip1 at the Y88 position and so promotes 
ubiquitination and subsequent degradation - exploiting a mechanism for normal 
cell cycle progression into S-phase (144). Correspondingly it has been seen that 
BCR-ABL inhibition (with IM) in cell lines and CD34+ cells from patients with CML, 
results in p27kip1 stabilisation and increased apoptosis (145). Furthermore, induced 
over-expression of p27kip1 in BCR-ABL+ cell lines reduces proliferation rates, with 
accumulation in G1 phase and this renders cells insensitive to PI induced 
apoptosis. It is also speculated, though unproven, that increased p27kip1 may be a 
mechanism for drug resistance in the quiescent stem cell population (146). The 
CDKi p21cip1/waf1 and p57kip2 and are related to p27kip1 and presumed to share 
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similar activity. Treatment of BCR-ABL+ and lung cancer cell lines with bortezomib 
is associated with stabilisation of p21cip1/waf1 and accumulation of cyclin B (147, 
148). p57kip2 is regulated in a similar manner to p27kip1 through SKP2 ubiquitin 
ligase activity and proteasomal degradation (149). However, effects of bortezomib 
on p57kip2 have not specifically been addressed in CML.  
 
Bortezomib has established antiproliferative effects in cell lines and tumour cells 
from solid organ and haematological malignancies including BC CML. This has 
been demonstrated with accumulation of treated cells in G2-M phase (1, 9, 150). It 
is likely ineffective cell division is mediated by a failure of the normal cyclical 
degradation of CDK complexes and CDKi and it is presumed the increased 
proliferative potential of malignant cells renders them more susceptible to these 
effects than their non-malignant counterparts. 
 
1.9.4.3 Bortezomib and apoptosis 
Apoptosis describes a coordinated process by which cells die. Apoptosis is 
initiated in several ways and of most importance are the “extrinsic” and “intrinsic” 
pathways. Extrinsic apoptosis is precipitated by the binding of a ligand (e.g. TNF) 
to a cell surface death receptor (e.g. TNF –related apoptosis inducing ligand, 
TRAIL receptor). In intrinsic apoptosis, cell death follows a series of intracellular 
events. Both pathways result in the characteristic changes of cell shrinkage, 
chromatin condensation, nuclear fragmentation, blebbing and the exposure of 
phosphatidyl serine on the outer cell membrane. The latter is exploited in 
experimental techniques demonstrating cell death (2.4.2). Cysteine protease 
cleaving after Asp (‘caspase’) enzymes are important in apoptosis and are 
synthesised as an inactive pro-caspase requiring specific cleavage for activation. 
This cleavage is inhibited by inhibitor of apoptosis (IAP) proteins. In general 
“initiator” caspases (e.g. caspases-8,-9 and -10) activate “executioner” capases 
(e.g. caspase-3 (2.4.3) and -7) which then precipitate apoptosis.  
 
The extrinsic pathway is stimulated by death receptor binding with consequent 
activation of caspases-8 and -10 through the adaptor molecule FAS-associated 
death domain-containing protein (FADD). In the intrinsic pathway the initiator is 
caspase-9, which is activated by formation of a complex with apoptosis protease 
activating factor-1 (APAF-1). This process requires cytochrome c release from the 
mitochondrion by membrane permeabilisation (MMP). With MMP, Cytochrome c 
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release is accompanied by second mitochondria-derived activator of caspase 
(SMAC) which binds and deactivates IAP (151). MMP is considered a critical 
phase of apoptosis and is influenced by the BCL-2 family of proteins, all members 
of which contain BCL-2 homology (BH) domains. They are either anti- or pro-
apoptotic. Anti-apoptotic factors include BCL-2, BCL-XL and MCL-1. The pro-
apoptotic members are subclassified as those with multiple BH domains (e.g. 
BAX, BAK) or only one (BH-3 only) domains (e.g. BIM, BID, BAD, NOXA and 
PUMA). Fundamental to MMP is the formation of molecular pores in the 
mitochondrial membrane and this is directly associated with the activation of BAX 
and BAK. BH3 only proteins indirectly contribute to this activity by either activation 
of BAX/BAK or by blocking the inhibitory activity of anti-apoptotic BCL-2 proteins. 
 
Though the two pathways are described separately, there is recognised cross-
activation. For example, TRAIL-stimulated caspase-8 activation mediates 
cleavage and activation of BID with resulting Cytochrome c release - hence linking 
the extrinsic and intrinsic pathways (152). 
 
Bortezomib has been shown to affect the balance of pro- and antiapoptotic factors. 
A key member of the BH3-subgroup of pro-apoptotic factors is BIM.  BCR-ABL 
may reduce BIM via ERK activity with resulting phosphorylation and proteasomal 
degradation. This influence on levels of BIM has been reversed with IM, nilotinib 
and PI exposure.  Furthermore, siRNA reducing expression of BIM has been 
shown to rescue cells and the BH3-mimetic ABT-737 enhanced IM-induced cell 
death.  These results have been generated from work with IM-sensitive and 
resistant cell lines and CML patient samples and have led to the suggestion that PI 
may be effective in combination with TKI (153-156). Other pro-apoptotic factors 
affected by bortezomib in various solid organ cell line models include NOXA (157, 
158) and BIK (though at 100-500nM bortezomib) (159). Effects have been seen on 
anti-apoptotic factors with possible upregulation of BCL-2 though this has not been 
a consistent finding (159). Full activation of BIM, BAK and BAK requires loss of 
MCL-1 through proteasomal degradation. In CML cell lines MCL-1 has been 
demonstrated as constitutively active - when targeted with siRNA to reduce MCL-1 
activity, cells undergo apoptosis. It is interesting to note in melanoma cells 
bortezomib treatment may enhance or stabilise MCL-1 by preventing breakdown 
(160). This observation is however consistent with the concept that PI shift the 
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balance towards apoptosis by influencing a number of factors rather than specific 
targeting of individual pathways. 
 
1.9.4.4 Bortezomib and reactive oxygen species generation 
Reactive oxygen species (ROS) are products of normal cellular processes and are 
involved in the initiation of apoptosis through stimulation of cytochrome c release. 
In the resting state ROS are stabilised through antioxidants such as glutathione. 
However following a disruption of the MMP there is an associated increased 
generation of ROS, saturating the antioxidant systems and resulting in the 
promotion of cell death (“bioenergetic crisis”) (reviewed in (151)). Bortezomib 
treatment of non-small cell lung cancer cell lines at 50-100nM is associated with 
enhanced generation of ROS. Inhibition of this ROS generation (with the 
antioxidant Tiron) reduced ROS generation and apoptosis (161). In a similar 
manner 5nM bortezomib induced ROS generation in BCR-ABL+ Ba/F3 cells (p210 
and T315I) with associated apoptosis which was partially reversed with antioxidant 
treatment (123).  
 
Adaphostin is a member of the tyrophostin group of TKI. These compounds 
interfere with peptide binding, in contrast to IM which affects the kinase ATP 
binding site. Adaphostin is a derivative of AG957, a drug developed as an 
alternative to IM. Adaphostin has been shown to induce apoptosis and reduce 
BCR-ABL expression in cell lines. The mechanism of action may involve the 
generation of ROS. Recent work has produced results in cell lines suggesting 
synergism with adaphostin and bortezomib, presumably related to the response to 
oxidative injury (123).  Minimal toxicity of adaphostin on normal human CD34+ 
cells was seen (124).  
 
1.9.4.5 Bortezomib and autophagy 
Autophagy is a pathway to cell death that is distinct from apoptosis. It is a process 
through which portions of the cytoplasm are enveloped and bound within the cell 
and then the contents digested by lysosomal enzymes. This enables elimination of 
abnormal intracellular proteins or damaged organelles. The process may be 
progressive with resultant destruction of the entire cell (reviewed in (151)). Of 
relevance to the proteasome is that the pathway is an additional mechanism for 
protein degradation, though it involves aggregation of the abnormal proteins 
(aggresome) and requires histone deacetylase (HDAC) activity. Studies have 
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shown that targeting of both the proteasome (with bortezomib) and the aggresome 
pathway (by tubacin a HDAC inhibitor) in multiple myeloma PB and BM cells 
results in synergistic accumulation of polyubiquitinated proteins and apoptosis 
even in the presence of supportive stromal cells (162). Bortezomib also was 
synergistic with LBH589 (a HDAC inhibitor) in multiple myeloma BM and PB cells 
though here evidence was presented for the role of inhibition of aggresome 
migration through tubulin deacetylase inhibition preventing autophagy (103). There 
is relevance here to CML as it has been demonstrated that TKI induce autophagy 
in BCR-ABL+ cells. This may be a protective response as concomitant exposure of 
cells to drugs which inhibit autophagy enhanced TKI induced cell death (163, 164). 
Suberoylanilide hydroxamic acid (SAHA, Vorinostat) is a HDAC inhibitor which is 
currently under investigation in clinical trials for haematological and non-
haematological malignancies, including BC CML. The mechanism of action 
includes both induction of apoptosis and autophagy, demonstrated by caspase-3 
activation and characteristic morphological changes seen under electron 
microscopy of HeLA cells (165). Treatment of BCR-ABL+ cell lines and patient BM 
samples, including those expressing T315I, with SAHA resulted in apoptosis that 
was independent of BCR-ABL activity. Apoptosis was enhanced when SAHA was 
used in combination with drugs known to target autophagy, which include 
chloroquine. 
 
1.9.5 Current clinical use of bortezomib 
 
1.9.5.1 Multiple myeloma 
Particular biological features of multiple myeloma (a malignant disorder of plasma 
cells) justified in vitro experiments exposing cell lines and BM cells from patients 
with this condition to bortezomib. In multiple myeloma IL-6 promotes growth and 
survival of the tumour cells and secretion of IL-6 is dependent on NFkB activity 
(166, 167) – as described (1.8.1.2.1) NFkB activity and proteasomal function are 
intricately connected. With bortezomib treatment, selective apoptosis and 
significant inhibition of cell growth was seen in comparison to normal PB MNC. 
Phase 1 clinical trials demonstrated particular efficacy in plasma cell dyscrasias 
(168) and phase 2 (169, 170) trials in multiple myeloma the safety and efficacy of 
a 1.3mg/m2 dosing regime with additive benefits seen when bortezomib was 
combined with dexamethasone. These findings formed the basis of the 
randomised phase 3 APEX (Assessment of Proteasome Inhibition for Extending 
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Remissions) trial which compared bortezomib monotherapy with high-dose 
dexamethasone in patients with relapsed multiple myeloma (171). Bortezomib was 
associated with higher response rates, a longer time to disease progression and 
improved survival. Data from these clinical trials led to the acceptance by the 
Scottish Medicines Consortium for restricted use of bortezomib in multiple 
myeloma as described (1.8).  
 
1.9.5.2 Mantle cell lymphoma 
The USA licensing for bortezomib in relapsed or progressive mantle cell 
lymphoma is based on supportive data generated from the phase 2 PINNACLE 
(Proteasome Inhibition as an Innovative Approach to Relapsed Mantle Cell 
Lymphoma a Single Agent Evaluation) trial. Here a similar dosing schedule to that 
of the APEX trial was seen to be safe and effective with approximately one-third of 
patients achieving a reduction in tumour burden (172). No submission has been 
made for a UK license for use in this setting though the drug is available for use as 
part of a clinical trial (www.cancerhelp.org.uk). 
 
1.9.5.3 Other haematological malignancies 
There are currently (December 2008) 194 open and recruiting trials using 
bortezomib for treatment of cancer patients. 10 trials involve treatment of patients 
with AML and of these 1 will accept patients with BC CML. All involve bortezomib 
as combination therapy. 
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Table 1.5 Current clinical trials with bortezomib in myeloid malignancy 
Disease Trial phase Additional therapies Trial number 
AML 1/2 mitoxantrone + etoposide NCT00410423 
AML 1/2 fludarabine + idarubicin + G-
CSF 
NCT00651781 
AML 2 tipifarnib NCT00510939 
AML 2 idarubicin + ara-C or 
etoposide + ara-C 
NCT00666588 
AML 2 daunorubicin and ara-C NCT00742625 
AML and CML-BC 1 tipifarnib NCT00383474 
AML 1 idarubicin NCT00382954 
AML 1 azacytidine NCT00624936 
AML  Not stated melphalan NCT00789256 
AML 1 decitabine NCT00703300 
 
1.9.6 Pharmacodynamics of bortezomib 
A number of clinical trials with bortezomib in solid organ (renal, colon, lung, breast, 
prostate, neuroendocrine and hepatocellular cancers) and haematological (both 
lymphoid and myeloid) malignancies have published and the particular 
pharmacokinetic features of this drug are described. Following intravenous 
administration in a phase 1 trial the plasma bortezomib concentration followed a 
biphasic elimination profile, with an initial half life <30 minutes. The plasma 
concentration of bortezomib varied from a peak of 1.5-7.5ng/mL at 1h and did not 
clearly correlate with proteasome inhibition measured in PB. The conclusion drawn 
was that plasma levels of drug may not a reliable method for predicting or 
measuring drug effect (173).  Millennium Pharmaceuticals provide data indicating 
a wide range of peak plasma concentrations (109-1300ng/mL) with the caveat “the 
pharmacokinetics of Velcade® as a single agent have not been fully 
characterised” (www.velcade.info). Myeloma patients (n=23) were specifically 
assessed for pharmacokinetic and pharmacodynamic data. Patients were treated 
with 1.3mg/m2 (standard dose) following a standard schedule and at day 11 of 
cycle 3 peak levels of 114.9±98.3ng/mL (299nM) and area under the curve at 48h 
of 85.2±18.7ng.h/mL (approximately equivalent to 5.3±1.2nM continuous 
exposure) were recorded (174). The majority of published trials rely on a 
standardised fluorometric method to determine a CT-L:T-L ratio and from this 
derive data on achieved levels of proteasome inhibition in PB cells (175).  From 
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animal data >80% proteasome inhibition is predictive of significant morbidity and 
mortality (134, 176), this data was extrapolated to clinical trials to predict a 
maximum tolerated dose of 1.96mg/m2 (177).  The current recommended dose is 
1.3mg/m2 twice weekly for 2 weeks followed by a 10 day rest period.  This 
approximates 70-83% maximal proteasome inhibition at 1h (168, 173, 174).  
Following peak levels of inhibition at 1h approximately 50% and <20% of peak 
activity are seen at 24 and 72 hours (h) respectively with levels returning to 
baseline prior to day 4 (i.e. next dose) (168, 178-180).  Data to indicate drug 
effects in tumour and BM tissue are conflicting. In a murine model of MM the levels 
of proteasome inhibition achieved in the tumour was approximately half that of the 
blood (176), however data from a phase I trial in prostate cancer showed levels in 
blood and tumour were equivalent. Proteasome inhibition achieved in the BM was 
assessed in 2 patients in this trial and the levels were approximately half that seen 
in the blood (173).  
 
1.10 The proteasome in CML 
There is evidence that the proteasome may provide a relevant therapeutic target in 
CML. BCR-ABL+ cells have significantly higher levels of proteasome activity 
relative to comparable BCR-ABL- cells (as measured by turnover of fluorescent 
substrate for CT-L activity).  Furthermore, relatively high activity in 6 diagnostic BM 
samples from patients with CML has been demonstrated (2). This is consistent 
with data from other malignancies.  
 
1.10.1 Published use of proteasome inhibitors in CML 
A number of in vitro studies of PI, including bortezomib, in CML have been 
published. These will be reviewed in detail in the Discussion chapter. Despite 
promising in vitro effects, there is little in vivo data.  A phase 2 study has been 
published in abstract form, where bortezomib was used as monotherapy in 7 IM-
refractory or intolerant patients.  Data suggest in vitro and in vivo effects from 
analysis of apoptosis of patient derived mononuclear cell samples. No cytogenetic 
responses were seen and no survival data were presented (181).  
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1.11 Rationale for this study 
There is promising published data and a logical rationale for the use of PI in CML.  
Targeting the proteasome may offer a solution to the two key problems with TKI 
therapy: that of IM resistance, commonly in the form of BCR-ABL mutations; and 
the relative insensitivity of the stem cell to TKI. Cell line studies have 
demonstrated that IM-resistant cells are susceptible to bortezomib (1) though 
particular effects on viability and proteasome activity in cells with specific BCR-
ABL+ mutations have not been presented. Little work has been published on the 
effects of bortezomib on the Ph+HSC though 2 groups have published CFU data 
(3, 8). Assays that have demonstrated TKI effects on the quiescent Ph+HSC 
population include CFSE tracking of cell division and FACS to obtain the 
CD34+38- population. This has not investigated in CML with bortezomib. The 
current clinical trial profile of bortezomib serves to demonstrate that PI are 
effective agents in combination with established therapies. There is preliminary 
published data with conflicting results in BCR-ABL+ cell lines with bortezomib in 
combination with IM (1, 155). Dasatinib is a more potent TKI than IM though has 
not been assessed in combination with bortezomib. Combination of these agents 
would establish whether potent inhibition of BCR-ABL and proteasome activity 
could result in synergistic effects on cell viability. This may be particularly relevant 
in the Ph+HSC as BCR-ABL activity has been shown to be relatively high in this 
population (4). These questions provide the basis of the novel work performed in 
this project which aims to enhance knowledge in this field and may provide the 
basis for a clinical trial.  
 
 50 
1.12 Stated hypotheses and aims 
 
The hypothesis as stated in the grant proposal:  
 
“Increased BCR-ABL expression in CML stem cells may lead to increased 
proteasome activity, therefore, simultaneous inhibition of both BCR-ABL tyrosine 
kinase and proteasome activity might induce CML stem cell specific apoptosis and 
this combined treatment could be clinically translated in the immediate future.” 
 
The individual aims are stated as follows: 
 
1 Effect of PI on viability and proliferation in BCR-ABL+ cell lines including 
those resistant to TKI 
2 Proteasome activity in BCR-ABL+ cell lines 
3 Effect of PI on BCR-ABL activity in BCR-ABL+ cell lines 
4  Effect of PI on viability and proliferation of CML patient samples 
5 Effect of PI on BCR-ABL activity in CML patient samples 
6 Proteasome activity of CML patient samples 
7 Effect of PI on primitive cells from CML patient samples 
8 Effect of PI on non-CML patient samples  
9 The potential synergistic effect of PI and TKI on viability and proliferation of 
BCR-ABL+ cell lines and CML patient samples. 
 
 
 51 
2. METHODS 
 
2.1 Reagents and Equipment 
 
2.1.1 Reagents 
 
Reagent Company and address 
2-mercaptoethanol Invitrogen, UK 
7-amino-actinomycin D (7-AAD, Via-ProbeTM 
solution) 
BD Biosciences 
Adenosine triphosphate (ATP) Sigma-Aldrich, UK 
Annexin V-FITC BD Biosciences 
Beta-mercaptoethanol Sigma-Aldrich, UK 
Bortezomib Janssen-Cilag International 
NV, Beerse, Belgium 
Bovine Serum Albumin/Insulin/Transferrin 
(BIT) 9500 
StemCell Technologies Inc., 
USA 
BSATM Protein Assay Kit Pierce, Rockford, USA 
Carboxy-fluorescein diacetate succinimidyl 
diester (CFSE)  
Invitrogen, UK 
Dasatinib Bristol-Myers Squibb, 
Princeton, USA 
Demecolcine (Colcemid®, N-Deacetyl-N-
methylcolchicine) 
Sigma-Aldrich, UK 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich, UK 
Dithiothreitol (DTT) Sigma-Aldrich, UK 
DNase I StemCell Technologies Inc., 
USA 
Dulbecco’s Phosphate Buffered Saline (D-
PBS) 
Sigma-Aldrich, UK 
ECL+TM Chemiluminescence solution GE Healthcare UK Ltd. 
FACSFlowTM BD Biosciences, San Jose, 
CA 
Fetal calf serum (FCS) Invitrogen, UK 
FIX and PERM kit Caltag laboratories, 
Burlingame, CA 
Full range Rainbow® recombinant protein Amersham Biosciences, 
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molecular weight marker (12-225x103Mr) Buckinghamshire, UK 
Granulocyte-Colony Stimulating Factor Chugai Pharma Europe, UK 
Human Serum Albumin 20% Scottish National Blood 
Transfusion Service 
Imatinib Novartis Pharma, Basel, 
Switzerland 
Isove’s modified Dulbecco’s media (IMDM) Sigma-Aldrich, UK 
Laemmli sample buffer Bio-Rad Laboratories, 
Hercules, CA 
L-Glutamine Invitrogen, UK 
Low density lipoprotein Sigma-Aldrich, UK 
Magnesium Chloride Sigma-Aldrich, UK 
MG132 Calbiochem®, Merck, 
Darmstadt, Germany 
MgCl2 Sigma-Aldrich, UK 
Non-fat dried milk Morrisons supermarket, UK 
Nonidet® P-40 Roche Diagnostics, 
Mannheim, Germany 
PE-conjugated rabbit anti-active caspase-3. BD Biosciences 
Penicillin/Streptomycin Invitrogen, UK 
Propidium iodide BD Biosciences 
Re-BlotTM Plus Antibody Stripping Solution 
 
Upstate, Temecula, USA 
Recombinant human Flt-3 ligand StemCell Technologies Inc., 
USA 
Recombinant human IL-3 StemCell Technologies Inc., 
USA 
Recombinant human IL-6 StemCell Technologies Inc., 
USA 
Recombinant human Stem Cell Factor StemCell Technologies Inc., 
USA 
Recombinant murine IL-3 Peprotech, NJ, USA 
RPMI-1640 media Sigma-Aldrich, UK 
10xTG buffer 
Tris (25mM pH 8.3)/Glycine (192mM) 
Bio-Rad Laboratories Ltd., UK 
10xTGS buffer 
Tris (100mM pH8.3)/Glycine (100mM)/SDS 
(0.1%)  
Bio-Rad Laboratories Ltd., UK 
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Tris-HCl Sigma-Aldrich, UK 
Trisodium citrate Sigma-Aldrich, UK 
Trypan blue Sigma-Aldrich, UK 
Tween®-20 (polyethylene glycol sorbitan 
monolaurate) 
Sigma 
Z-ARR-AMC Calbiochem 
Z-LLE-AMC Calbiochem 
Z-Succ-LLVY-AMC Calbiochem 
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2.1.2 Equipment 
 
Equipment Use Company 
Branson 200 Ultrasonic 
cleaner 
Sonication of 
proteasome activity 
lysates 
Kell-Strom, 
Wethersfield, USA 
Cimarec® hot plate Adhesion of MeltiLex® 
and FIltermat A prior to 
scintillation counting 
Barnstead International, 
Thermo Fisher 
Scientific, Iowa USA 
Criterion® Blotter Filter 
paper 
Western blot Bio-Rad Laboratories 
Ltd., UK 
Epson Perfection 4490 
Photo Scanner 
Western blot Epson UK Ltd. 
FACSAria  Cell sorting 
FACSCaliber Flow cytometry 
BD Biosciences, San 
Jose, CA 
Gilson Pipetman Single 
channel Pipettes 
Pipetting Gilson, Inc., Middleton, 
USA 
Haemocytometer Cell counting Hawksey, UK 
Kodak X-OMAT 1000 Development of 
photographic film 
Carestream Health Inc., 
Rochester, NY, USA 
MicroBeta FilterMate-96 
Harvester 
Cell harvesting prior to 
analysis with scintillation 
counter 
MicroBeta Trilux beta-
scintillation counter 
Cell line proliferation 
PerkinElmer Life and 
Analytical Sciences, 
Milano, Italy 
Mini-PROTEAN® 3 cell SDS-PAGE Bio-Rad Laboratories 
Ltd., UK 
Multiscan EX 
photometer 
Protein concentration 
estimation 
Thermo Fisher Scientific 
Nitrocellulose 
membrane 
Western blot Bio-Rad Laboratories 
Ltd., UK 
PowerPac300 Electrophoresis and 
Semi-dry transfer in 
Western blot 
Bio-Rad Laboratories 
Ltd., UK 
Spectramax M5 Proteasome Activity 
Assay 
Molecular Devices 
Thermoshaker 95C incubation in 
Western blot 
Schutron, Reutlingen, 
Germany 
Trans-Blot® SD Cell Semi-dry transfer in 
Western blot 
Bio-Rad Laboratories 
Ltd., UK 
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2.1.3 Antibodies for Western blotting and Flow Cytometry 
 
Antibody Use Company 
Anti poly (ADP-ribose) 
polymerase (PARP), 
(rabbit) 
Western blot Cell Signaling 
Technology, Inc. 
Danvers, USA 
Anti active caspase-3 Flow cytometry BD Biosciences, San 
Jose, CA 
Anti rabbit IgG, HRP-
linked 
Western blot Cell Signaling 
Technology, Inc. 
Danvers, USA 
Anti mouse IgG, HRP-
linked 
Western blot Cell Signaling 
Technology, Inc. 
Danvers, USA 
Anti ubiquitin (P4D1) 
(mouse) 
Western blot Cell Signaling 
Technology, Inc. 
Danvers, USA 
Anti phosphorylated Crkl 
(rabbit) 
Western blot Cell Signaling 
Technology, Inc. 
Danvers, USA 
Anti p27kip1 (rabbit) Western blot Cell Signaling 
Technology, Inc. 
Danvers, USA 
Anti pan-actin (rabbit) Western blot Cell Signaling 
Technology, Inc. 
Danvers, USA 
Anti CD34-APC Flow cytometry BD Biosciences, San 
Jose, CA 
Anti CD38-FITC Flow cytometry BD Biosciences, San 
Jose, CA 
Annexin V-FITC Flow cytometry BD Biosciences, San 
Jose, CA 
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2.2 Drugs 
The drugs were stored as aliquots as follows: dasatinib as 10mg/mL (2.05mM - 
based on molecular weight 488.01) in dimethyl sulphoxide (DMSO) at -20˚C; 
imatinib mesylate as 59mg/mL (100mM based on molecular weight 589.7) in 
sterile distilled water at 4˚C; MG132 as 48mg/mL (100mM based on molecular 
weight 475.6) in sterile D-PBS at -20˚C; and bortezomib as 1mg/mL (2.6mM based 
on molecular weight 384.24) in sterile 0.9%NaCl at -20˚C. 
 
2.3 Cell lines and patient samples 
 
2.3.1 Cell lines 
Three cell lines were used. K562 cells are a BCR-ABL+ immortilised human cell 
line derived from a patient with BC CML (182, 183). HL60 are a human 
promyelocytic leukaemia cell line (BCR-ABL-). Ba/F3 cells are a mouse pro-B cell 
line. Wild-type (WT) Ba/F3 are BCR-ABL- and dependent on IL-3 for growth. 
Ba/F3 cells transfected with BCR-ABL (BCR-ABL+ Ba/F3) grow independently of 
IL-3.  Used here were Ba/F3 transfected with p210 (unmutated, Ba/F3-p210) or 
with mutated BCR-ABL (BaF/3-T315I, Ba/F3-H396P and BaF3-M351T).  
 
All cells were cultured in suspension (humidified incubator at 37˚C and 5%CO2) in 
RPMI-1640 media supplemented as shown (RPMI-1640 cell culture media 2.8.1).  
WT-Ba/F3 required addition of IL-3 at 10ng/mL. All cells were counted every 2-3 
days and resuspended in fresh media at a concentration of approximately 
2x105cells/mL. 
 
2.3.2 Patient samples 
Patient samples were leukapheresis products taken at time of diagnosis with CP 
CML, with informed consent and approval of the NHS Greater Glasgow 
Institutional Review Board. The CD34+ population was enriched using CliniMACS 
(Miltenyi Biotech, Auburn, CA) according to standard protocols, prior to storage as 
aliquots at -150ºC. For particular experiments CML CD34+ samples were stained 
with CD34-APC and CD38-FITC and sorted using a FACSAria to obtain the 
CD34+38- population, which represent primitive HSC.  
 
Prior to use, patient samples were rehydrated in 10mL DAMP solution (2.8.2 
incubated at 37ºC prior to use) added drop-wise to the cell solution.  The solution 
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was washed in DAMP solution three times (1000rpm for 10 minutes). Following 
the third wash the pellet was suspended in 10mL of serum free medium (SFM 
2.8.3) with a 5 growth factor cocktail (+5GF 2.8.4) in a 25mL tissue culture flask.  
SFM+5GF was used for all CML and non-CML samples except where stated SFM-
5GF.  The cells were maintained overnight in a humidified incubator at 37ºC and 
5% CO2.  The cells were counted and assessed for viability by trypan blue 
exclusion prior to use.   
 
2.4 Viability and apoptosis assays 
 
2.4.1 Assessment of viable cell counts 
Cells were counted by vital dye exclusion. An equal volume of a 0.8mM Trypan 
blue solution was added to an aliquot of the sample under investigation. The cell 
count was then performed by light-microscopy using a haemocytometer under x40 
magnification. The viable cell count was the number of cells which had maintained 
membrane integrity with exclusion of dye. All counts were performed as a 
minimum in duplicate. 
 
2.4.2 Apoptosis assays using flow cytometry 
Cells were assessed for the presence of early and late apoptosis using annexin V-
FITC and 7-amino-actinomycin D (7-AAD). One of the early changes of apoptosis 
is the translocation of phosphatidyl serine from the inner to outer cell membrane 
leaflet. As a consequence of this translocation phosphatidyl serine is then 
available for binding by Annexin-V. Cells will continue to bind Annexin-V even 
once membrane integrity is breached and the cell has died.  The vital dye 7-AAD 
will only bind cells where the membrane integrity is lost (as with Trypan blue and 
propidium iodide, PIo).  7-AAD was used in conjunction with Annexin-V to 
distinguish cells in early and late apoptosis (Annexin-V+ 7-AAD- versus Annexin-
V+ 7-AAD+) (Figure 2.1).  
 
Cells were cultured in appropriate media and exposed to drug prior to analysis at 
the stated times.  For the drug wash-out experiments, cells were cultured in drug-
containing media which was replaced with drug-free media (two washes in D-PBS 
with a 5 minute 1200rpm spin) at stated times with all aliquots analysed at 72h.  
For the apoptosis assay, samples were spun (1200rpm for 5 minutes) then 
resuspended in 100µL binding buffer (10mM Hepes/NaOH (pH7.4), 140mM NaCl, 
 58 
2.5mM CaCl2) and incubated in the dark, at room temperature, with the 
fluorescent-labelled antibody for 15 minutes (5µL annexin-V and 10µL Via-Probe 
solution/1x105cells). 400µL of binding buffer was added to each sample and then 
analysed immediately.  The use of non-viable, unlabelled and single-labelled 
controls provided appropriate compensation between channels prior to analysis of 
the experimental arms.  Annexin-V was labelled with FITC and so analysed in FL1, 
7-AAD was detected in FL3. The viable cell count was derived from the cell count 
by trypan blue exclusion and light microscopy. It was assumed that this count 
represented the total 7-AAD negative population (by flow cytometry). The ratio of 
cells staining both negative for annexin-V and 7-AAD compared to all 7-AAD 
negative cells could then be applied to the trypan blue cell count (assumed equal 
to all 7-AAD negative cells) to get a more accurate “viable cell count by flow 
cytometry” which would then take account of cells in early apoptosis. The 
percentage of cells in early and late apoptosis was used to give a total percentage 
apoptosis.   
 
Figure 2.1 Determination of cells undergoing apoptosis by flow cytometry with 
Annexin-V and 7-AAD staining 
 
2.4.3 Intracellular caspase staining 
A key regulator activated during the early stages of apoptosis is caspase-3. The 
presence of this enzyme is an accepted marker for cells undergoing apoptosis. 
The mAb recognises the active form in human and mouse cells. Here we used a 
monoclonal rabbit antibody (mAb) conjugated to PE which recognises the active 
form of caspase-3 in mouse and human cells.  
 
This technique required flow cytometry to assess binding of the labelled antibody 
to intracellular antigens and was performed using the FIX and PERM kit. Cells 
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were spun (1200rpm for 5 mins) and the pellet resuspended in 100µL of Reagant 
A (a formaldehyde-containing commercial solution for cell fixation) and then 
incubated at room temperature for 15 mins.  The cells were then washed in D-PBS 
as before and the pellet resuspended in 100µL of Reagant B (commercial cell 
permeabilisation solution).  10µL of PE-labelled anti-caspase-3 antibody was 
added and the samples incubated in the dark for 60 mins. Prior to flow cytometry 
the samples were washed twice in D-PBS (each spin 1200rpm for 5 mins). For 
each experiment an unstained and isotype control was used to set analysis 
parameters.  
 
2.4.4 Thymidine proliferation assay 
This assay was to assess proliferation of cell lines in the presence of drug.  It was 
assumed that incorporation of 3H-thymidine was proportional to the rate of 
proliferation at the time of analysis. Cells seeded at 2.5x105/mL in a 96-well plate 
and exposed to relevant concentrations of drug. On the day of analysis a 
0.2µCi/mL solution of 3H-Thymidine in RPMI-1640 cell culture media was added to 
each sample. Following 4h incubation cells were harvested onto a printed 
glassfibre filtermat (Filtermat A), which was then sealed with a melt-on scintillator 
sheet (MeltiLex® A) at 95°C and placed in a sample bag prior to analysis with a 
beta-scintillation counter. Each experiment was performed as a minimum in 
triplicate. 
 
2.4.5 CFSE staining  
 
2.4.5.1 Background  
This technique has an established role in tracking cells as they undergo division 
(184) and was applied to total CD34+ patient samples to assess the effects of drug 
treatment. CFSE crosses freely into cells where endogenous esterases remove 
acetate groups rendering CFSE membrane-impermeable and highly fluorescent. 
In addition, the succinimidyl group forms stable covalent bonds with intracellular 
proteins. In effect the molecule is “trapped” within the cell and divided equally 
between daughter cells with each cell division. This stepwise reduction in cell 
fluorescence was visualised by flow cytometry (FL1 channel) enabling estimation 
of the number of divisions a sample of cells has undergone. The protocol 
described here was adhered to. 
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2.4.5.2 Day 0  
CD34+ CML patient samples were taken from liquid nitrogen storage and 
rehydrated by drop-wise addition over 10mins of 10mL of an ice-cold solution of 
2% FCS in D-PBS (FCS/PBS). The cells were then washed twice (1000rpm for 
10mins) in 10mL 2% FCS/PBS, resuspended in 5mL of 2% FCS/PBS, transferred 
to a sterile 50mL tube and counted by dye exclusion (as described above). 2 
aliquots of 0.5x106cells were removed and made up to 1mL (for day 1 analysis) 
and 2mL (day 3 analysis) with SFM+5GF (CFSE-). The remaining cell solution was 
made up to 5mL with 2% FCS/PBS. CFSE (stored as aliquots of 5mM in DMSO at 
-20ºC) was added to this sample to give a final concentration of 1µM. Once CFSE 
was added the sample (CFSE+) underwent 10mins timed incubation in a water 
bath at 37ºC. 50mL of ice-cold 20% FCS/PBS (quenching solution) was added and 
the cells spun and then washed in 2% FCS/PBS (both 1000rpm for 10mins). The 
cells were then resuspended in 10mL of SFM+5GF in a 25mL sterile flask. CFSE+ 
and CFSE- samples were incubated overnight at 37°C and 5% CO2. 
 
2.4.5.3 Day 1  
Sufficient SFM+5GF was added to the CFSE+ cells to give a final concentration 
2.5x105cells/mL. 500µL samples were added to a 48-well plate and exposed to the 
relevant experimental conditions. For each experiment 2 samples were treated 
with 100ng/mL demecolcine (Colcemid®, stored as a 25ng/mL stock solution at 
4ºC). Demecolcine arrests the cell cycle in metaphase by depolymerising 
microtubles and was used to determine the position of the undivided population by 
flow cytometry at day 3. In addition, 3 unstained and 3 CFSE-stained controls 
were used. All experimental samples were incubated for 72h at 37°C and 5% CO 2.  
 
2.4.5.4 Day 3   
Each sample was well mixed and a cell count performed. The samples were 
transferred to a FACS tube with an additional rinse of each well (2% FCS/PBS) to 
minimise wastage. The cells were spun (1200rpm for 5mins) and the supernatant 
discarded. To determine CD34+ cells, 5µL CD34-PE antibody was added to each 
pellet (excluding controls) the samples mixed and left at room-temperature for 
15mins. The samples were then washed twice with 2% FCS/PBS (1200rpm for 
5mins). To determine viable cells, 2µL propidium iodide (PIo) in 2mL 2% FCS/PBS 
was added to each sample (excluding controls). Viable cell membranes are 
impermeable to PIo however this dye will bind the DNA of on viable cells with 
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disrupted membranes and once bound displays enhanced fluorescence. The were 
cells then spun (1200rpm for 5mins), the supernatant discarded to remove 
unbound PIo and the pellet resuspended in a small volume of FACSFlowTM (a 
commercial PBS/azide solution) and then analysed by flow cytometry. The 
controls (CFSE+ with PIo, CFSE+ with PIo and CD34-PE, CFSE- with PIo and 
CFSE- with PIo and CD34-PE) enabled appropriate detection of the live cells on 
forward (FSC) and side-scatter (SSC) with adequate compensation between the 
channels FL1 (detecting CFSE), FL2 (PE) and FL3 (PIo). 
 
2.4.5.5 Calculation of cell numbers  
The number of viable cells was estimated by trypan blue cell count at days 0, 1 
and 3. At day 3 a gate was created on the forward and side-scatter plots to include 
cells and exclude cell debris. The focus of analysis was then limited further by 
gating only on viable (PIo-) and CD34+ cells. From this population, undivided cells 
were assumed to be those with CFSE fluorescence of an intensity comparable to 
the Colcemid® control (PIo-CD34+CFSEMAX). A region was set around this peak 
to include all cells with comparable CFSE staining. Subsequent division peaks 
were set by calculating regions where the mean CFSE fluorescence intensity was 
approximate half that of the preceding region. For assessment of the CD34+ 
percentage for each division peak only PIo- cells were included. For assessment 
of the percentage of cells in each division viable (PIo exclusion) cells both CD34+ 
and CD34- were included. Calculation of the cell recovery was a method for 
determining how many of the seeding population of cells (presumed to be 
undivided) could be accounted for at day 3 – a formula was applied (Equation 2.1) 
where R=recovery number n0= number of undivided cells, n1=number of cells in 
division 1, n2=number of cells in division 2, n3=number of cells in division 3 and so 
on. 
 
   .....
432
321
0
nnn
nR +++=   Equation 2.1  
 
The recovery number was then compared (as a percentage) to the known input 
number to calculate a recovery percentage. The percentages could then be 
compared to the no drug control arm. The day 3 recovery of viable undivided cells 
(CD34+PIo-CFSEMAX) was also compared between the experimental arms.  
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2.5 Western Blotting 
 
2.5.1 Estimation of protein concentration 
The BSATM Protein Assay Kit was used. This method exploited the colour change 
associated with the reduction of copper ions by protein in alkaline conditions. The 
colour change was detected as absorption at 550nm by photometer. Standards of 
known protein concentration were made from dilutions (5µg/mL to 1500µg/mL) of 
bovine serum albumin in water. These were loaded as duplicate 25µL samples in 
a 96-well plate. Aliquots of the sample under analysis were added, in duplicate, as 
a 1:5 dilution in water (5µL sample and 20µL water).  To each well was added 
200µL of a mixture of the alkaline BCATM Solution A (50 parts) and the copper-
containing BCATM Solution B (1 part). The plate was incubated for 30mins at 37°C 
and loaded on a photometer with light absorbance measured using a 550nm filter. 
The software (Ascent v2.6) plotted a derived linear-plot of protein-concentration to 
absorbance and provided estimation of the protein concentration of the diluted 
sample.  
 
2.5.2.1 Preparation of sample lysates  
Following 2 washes in ice-cold D-PBS (1200rpm for 5 mins), samples were re-
suspended in ice-cold 150µL lysis buffer (50mM Tris pH7.5, 150mM NaCl, 5mM 
EDTA, 1% Nonidet® P-40 substitute 2.8.5) containing a protease inhibitor cocktail 
(1 “Complete” Protease Inhibitor Cocktail tablet per 10mL lysis buffer).  Following 
10 minutes incubation on ice samples were spun (14000rpm for 10 minutes at 
4˚C) and the supernatant removed for analysis, including estimation of protein 
concentration as described above. Samples were stored at -80°C. 
 
2.5.2.2 SDS-PAGE electrophoresis  
10mcg of the protein lysate was made up to 10µL with H2O and mixed with an 
equal volume of loading buffer (2.8.6). The samples were incubated at 95°C for 5 
minutes, returned to ice then immediately loaded onto a 4-15% sodium dodecyl 
sulphate gradient gel immersed in running buffer (2.8.7). The samples were 
separated at 120V for 90mins using the Mini-PROTEAN® 3 cell system. For each 
gel a molecular weight Rainbow® marker sample was run.  
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2.5.2.3 Electrophoretic transfer  
A semi-dry transfer method was followed, using a Bio-Rad Trans-blot® SD cell. 
The gel “sandwich” was made as shown in Figure 2.2 and run at 10V for 30mins: 
 
 
Figure 2.2 Gel “sandwich” used for electrophoretic transfer 
 
The nitrocellulose membrane and filter papers were soaked in transfer buffer 
(2.8.8) prior to use. To prevent non-specific protein interactions with nitrocellulose, 
the membrane was incubated for 1h at room temperature with 5% milk in TBS-T 
(2.8.9/10) buffer (blocking solution). This and all subsequent washes and antibody 
incubations were performed with gentle agitation on a mixer platform 
 
2.5.2.4 Primary and secondary antibody incubation  
Following exposure to the blocking solution, which was discarded, the membrane 
was incubated overnight (4ºC) with the primary antibody of interest (1:1000 dilution 
in 10mL TBS-T with 1% milk). The following morning, the membrane was washed 
4 times with TBS-T. Each wash was 15mins on a mixer platform with sufficient 
buffer to completely cover the membrane. Membranes were then labelled with the 
appropriate horseradish peroxidase-labelled secondary antibody (1:3000 dilution 
in TBS-T with 1% milk) and incubated at room temperature for 1h.  After a further 
series of 4 washes of 15mins in TBS-T and a short incubation (2-5mins) with an 
ECL+TM chemiluminescence solution, the images were developed onto 
photographic film. The membranes were then stripped of bound antibody using 
Re-BlotTM solution (15mins incubation at room temperature). Prior to probing with 
different primary antibodies the membrane was twice washed for 5mins with 5% 
milk in TBS-T. 
 
2x filter paper 
2x filter paper 
gel 
membrane 
ANODE 
CATHODE 
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2.6 Proteasome extraction and activity assay 
This followed an established method for preparing cell lysates with preserved 
proteasome activity. The lysates were then incubated with individual fluorogenic 
substrates for each of the 3 enzymic activities of the proteasome. The release of 
the fluorescent substrate was detected by the fluorimeter and enzymic activity 
compared between different experimental conditions. 
 
Cells (1x107) were washed in D-PBS and resuspended in fresh 1mL ATP/DTT 
lysis buffer.  After 10 minutes incubation on ice, the cells were sonicated and then 
spun for 10 minutes at 13000rpm.  The supernatant was collected and protein 
concentration calculated (as described in 2.5.1). Samples were either analysed 
immediately or mixed with 20% glycerol and stored at -80ºC.  The fluorogenic 
substrates N-Succ-LLVY-AMC, Z-ARR-AMC and Z-LLE-AMC (used to measure 
CT-L, T-L and PGH-L activities respectively) were stored protected from light, at -
20ºC as 10mM stock solutions in DMSO. The assay was carried out in ATP/DTT 
lysis buffer (2.8.11) containing 50µg of the protein extract, 5mM EDTA and 50µM 
fluorogenic substrate in an opaque-walled 96-well plate. Analysis by a dual-
monochromator, multi-detection microplate reader immediately followed addition of 
the fluorescent substrate. Activity was represented by the release of fluorescent 
substrate at excitation and emission wavelengths of 380nm and 460nm 
respectively (manufacturer’s recommendations). Readings were taken every 
5mins for 35mins and expressed as arbitrary fluorescence units (AFU). The 
equation of the linear rise in AFU per unit time was used to determine the rate of 
fluorescence release (AFU/min). 
 
2.7 Software and Statistical Analysis 
 
2.7.1 Software used for data analysis 
GraphPad Prism® (version 4, California USA) was used to draw graphs, charts, 
calculate descriptive statistics, predict dose-response curves and perform 
statistical analysis. The concentration of drug shown to achieve a 50% reduction in 
viable cell count was termed LD50. This figure was estimated from the dose 
response curves predicted using Prism® software. Flow cytometry data was 
analysed by CellQuest Pro software (BD Bioscience). Fluorimetry data was 
analysed by both SpectraMax® Pro 5 (derivation of numerical data) and Microsoft 
Excel® software (analysis of numerical data). 
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2.7.2 Analysis of data from synergism experiments 
To assess synergism, dose-response data generated from drugs used individually 
and in combination were analysed with CalcuSyn® (Version 2.0 Biosoft, 
Cambridge, UK). The underlying mathematical model is described in detail by 
Chou (185) and is outlined here. For this analysis a number of calculations were 
performed by the software (Equations 2.2-2.4). Prior to input of data, the viable 
cell count (as a percentage of untreated control) was converted to an effect 
(Equation 2.2) where fa is the fraction affected and VCC% the viable cell count 
expressed as a percentage of untreated cells.  
 
100
%1 VCCf a −=     Equation 2.2 
 
The median-effect equation (equation 2.3) forms the basis of the Calcusyn® 
software analysis, where D was the dose of a drug, fa the fraction affected by D 
(percentage inhibition/100), fu the fraction unaffected (1-fa) and Dm the median 
effect dose (=LD50 as used here).  
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The logarithm of equation 2.3 formed the median-effect plot (equation 2.4) which 
converted the dose-effect curve to a straight line where m was the slope and Dm 
the anti-log of the x-intercept. 
 
( ) ( )m
u
a DmDmf
f logloglog −=   Equation 2.4 
 
The data was then assessed for conformity by generation of an r-value (where 
r>0.95 was accepted). For the combination of two drugs a fixed ratio of 
concentrations was applied and this is illustrated in Figure 2.4.  
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Figure 2.3 Checker-square analysis of drug combinations. Drugs were analysed 
for effect individually (█) and then in combination at fixed ratios (█,█,█). It is this 
data that was analysed using Calcusyn®. The numbers shown indicate multiples 
of the drug concentration required to achieve a 50% effect. 
 
This data was then analysed within the software by equation 2.5 where (Dx)1 was 
the concentration of Drug 1 causing x% inhibition, (Dx)2 the concentration of Drug 2 
with x% inhibition and (D)1+(D)2  the concentration of Drug A and B with the same 
(x) degree of inhibition. 
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DCI +=     Equation 2.5 
 
Therefore a ratio is derived (Combination Index, CI) where >1 indicates 
antagonism, <1 synergism and 1 an additive effect. The degree of synergism 
corresponds to the CI as shown in Table 2.1. 
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Table 2.1 Assessment of synergism by combination index 
CI range description Graded symbols 
   
<0.1 Very strong synergism +++++ 
0.-0.3 Strong synergism ++++ 
0.3-0.7 synergism +++ 
0.7-0.85 Moderate synergism ++ 
0.85-0.9 Slight synergism + 
0.9-1.1 Nearly additive ± 
1.1-1.2 Slight antagonism - 
1.2-1.45 Moderate antagonism -- 
1.45-3.3 antagonism --- 
3.3-10 Strong antagonism ---- 
>10 Very strong antagonism ----- 
   
Table adapted from Chou TC (185) 
 
Data are also displayed as a conventional isobologram (Figure 2.4) where 
selected linear additive effects are plotted on a graph of (Drug A, Drug B). 
Experimental data was then shown and compared to these linear plots as 
synergistic (below the line), additive (on the line) or antagonistic (above the line).  
 
Figure 2.4 Illustration of isobologram. The broken line indicates additive effect (for 
example LD50) when considering two drugs (Drug A, Drug B). Experimental data 
may reveal ○ synergistic, x additive or ▲ antagonistic effects in combination. 
+ 
○ 
▲ 
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2.8 Culture media and other stock solutions 
 
2.8.1 RPMI-1640 Cell Culture Medium for culture of cell lines 
 Final concentration 
Penicillin/Streptomycin 1x105units/L and 100mg/L 
Glutamine 2mM 
Foetal calf serum 10% 
Made up in 440mL RPMI 1640 
 
2.8.2 DAMP solution for rehydration of stem cells 
 Final Concentration 
DNase I 10000units/L 
Magnesium Chloride 2.5mM 
Trisodium citrate 16mM 
Human Serum Albumin 20% 1% 
Made up in 418.75mL D-PBS 
 
2.8.3 Serum Free Medium for culture of stem cells 
 Final concentration 
Bovine Serum Albumin/Insulin/ Transferrin 
(BIT9500) 
 
L-Glutamine 2mM 
Penicillin/Streptomycin 1x105units/L and 100mg/L 
2-Mercaptoethanol 0.1mM 
Low density lipoprotein 0.8µg/mL 
Made up in 97.25mL Isove’s modified Dulbecco’s media (IMDM) 
 
2.8.4 5-Growth Factor Cocktail used with SFM for stem cell culture 
 Final concentration 
IL-3 20ng/mL 
IL-6 20ng/mL 
Flt3 100ng/mL 
Stem cell factor 100ng/mL 
Granulocyte-Colony Stimulating Factor 20ng/mL 
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2.8.5 Protein lysis buffer for Western blot 
 Final concentration* 
Tris pH7.5 50mM 
Sodium chloride 150mM 
EDTA 5mM 
Nonidet® P-40 substitute 1% 
*Made in ddH20 
 
2.8.6 Loading buffer for Western blot 
 Volume per mL 
Laemmli sample buffer 950µL 
Β-mercaptoethanol 50µL 
 
2.8.7 Running buffer for Western blot 
 Volume per L 
10xTGS buffer 100mL 
ddH20 900mL 
 
2.8.8 Transfer buffer for Western blot 
 Volume per L 
10xTG buffer 100mL 
Methanol 200mL 
ddH20 700mL 
 
2.8.9 10xTBS buffer for Western blot 
 Final concentration* 
Tris-HCl, pH 8 0.1M 
NaCl 1.5M 
*Made in ddH20 
 
2.8.10 TBS-T Washing buffer for Western blot 
 Volume per L 
10xTBS 100mL 
ddH20 900mL 
Tween®-20 1mL 
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2.8.11 ATP/DTT lysis buffer for proteasome activity assay 
 Final Concentration* 
Tris-HCl, pH7.8 10mM 
DTT† 0.5mM 
ATP† 5mM 
MgCl2 5mM 
*Made in ddH20 †Aliquots of DTT and ATP were stored at 4ºC and -20ºC 
respectively and added immediately prior to use. 
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3. RESULTS 
 
Aim 1 Effect of PI on viability and proliferation in BCR-ABL+ cell lines 
including those resistant to TKI. 
 
The initial investigation of the effects of bortezomib exposure on BCR-ABL+ cells 
focussed on the proliferation and viability of cell line models for CML. Those used 
were K562 and BCR-ABL+Ba/F3 cells. K562 cells are an immortilised human cell 
line derived from a patient with CML BC and are an established model for 
monitoring drug effects (182). Ba/F3 cells are murine, IL-3 dependent 
haematopoietic cells which may be reliably transfected with BCR-ABL thus 
rendering their growth IL-3 independent. BCR-ABL+ Ba/F3 cells are an 
established model for monitoring the effects of TKI (90). To achieve this aim it was 
also considered important to ensure that the effects of the drug were not 
influenced by the storage conditions used. 
 
3.1. Bortezomib is antiproliferative and induces apoptosis in BCR-ABL+ cell 
lines 
 
3.1.1 Cell counting and Flow cytometry 
BCR-ABL+ cell lines (K562 and Ba/F3-p210) were maintained in RPMI-1640 cell 
culture media and exposed to concentrations of bortezomib (1 to 40nM) for set 
time periods (24, 48 and 72h). For these initial experiments, dose-response curves 
for drug effect were established in K562 by cell counting at 24, 48 and 72h with 
vital dye exclusion. The cells were cultured in cell culture media containing 
bortezomib added at the start of the experiment with no additional dosing or drug 
wash-out. It was seen that an increase in bortezomib concentration was 
associated with a decrease in viable cell count (Figure 3.1). Estimated LD50 for 
K562 were 6.4nM (24h) 5.6nM (48h) and 11.2nM (72h) (Table 3.1).  
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Figure 3.1. K562 cells were exposed to bortezomib for 24h (▬●), 48h (▬▲) and 
72h (▬▼) with the viable cell count expressed as a percentage of untreated cells. 
Points and error bars indicate mean±SEM and adjoining lines demonstrate dose-
response curves of best fit. 
 
K562 cells were then examined at 24, 48 and 72h of bortezomib exposure for 
early/late apoptosis by flow cytometry (as described in 2.4.2). It was shown that 
with increasing concentration of bortezomib there was an increase in the 
percentage of cells staining positive for annexin-V alone (early apoptosis) and both 
annexin-V and 7-AAD (late apoptosis).  
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Figure 3.2. (A) K562 cells were exposed to bortezomib and then analysed by flow 
cytometry to determine the total % cells undergoing apoptosis. Results from 24h 
(■) 48h (■) and 72h (■) drug exposure are shown. (B) K562 cells exposed to 
bortezomib for 48h and analysed as in (A) then displayed to show the % cells in 
either early or late apoptosis. Error bars indicate mean±SEM. Annexin-V (An), 
detection/no detection of bound fluorophore by flow cytometry (+/-). 
 
A combination of vital dye exclusion and flow cytometry (as described in 2.4.2) 
was used to compare the effect of bortezomib on Ba/F3 p210 with Ba/F3 BCR-
ABL mutants (Ba/F3-M351T Ba/F3-H396P and Ba/F3-T315I) (Figure 3.3). LD50 
results were similar between the 4 BCR-ABL+ Ba/F3 transfectants (Table 3.1) 
though there was a trend for the mutant forms to be slightly less sensitive than 
Ba/F3-p210.  
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Figure 3.3. BCR-ABL+ Ba/F3 cells were exposed to bortezomib for 24h and then 
analysed by cell counting and flow cytometry to determine (A) the reduction in 
viable cell count (as a % of untreated cells) and (B) the increase in the % of cells 
in early and late apoptosis. Points and error bars in both (A) and (B) indicate 
mean±SEM and adjoining lines demonstrate dose-response curves of best fit. 
Ba/F3-p210 (--■--) BaF3-M351T (--□--) Ba/F3-H396P (--◊--) Ba/F3-T315I (--○--).  
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Table 3.1. Estimation of bortezomib LD50
 
by cell counting and flow cytometry in 
BCR-ABL+ cell lines 
Cell type Exposure time LD50 (nM) Figure 
K562 24h 6.4 
 48h 5.6 
 72h 11.2 
3.1 
Ba/F3-p210 6.3 
Ba/F3-H396P 10.8 
Ba/F3-M351T 11.3 
Ba/F3-T315I 
All 24h 
8.5 
3.3(A) 
 
3.1.2 Bortezomib stability 
It is the recommendation of Janssen-Cilag International that bortezomib is 
administered to patients immediately following reconstitution in sterile 9mg/mL 
NaCl for injection (bortezomib Summary of Product Characteristics August 2008). 
Independent studies have shown the drug to be stable up to 42d after once 
reconstituted in this way and stored at 4-5°C or ro om temperature (23°C) (186, 
187).  Here we used aliquots of reconstituted bortezomib stored initially at 4°C for 
<24h and then as aliquots at -20ºC. Other researchers have reconstituted and 
stored bortezomib in a variety of ways. These include reconstitution and storage in 
DMSO (-20°C(1, 5, 9), -80°C (188) or no temperature  stated (123)), Me2SO (no 
temperature stated), PBS (-20°C (3) or no temperatu re stated) (159, 161) and 
9mg/mL NaCl (-70°C (88) or no temperature stated (8 )). To ensure that the 
method of storage that we adopted did not influence the drug effect we assessed 
the ability of fresh and stored bortezomib to induce cell death in K562 cells (Figure 
3.4). This experiment was performed only twice and so sufficient data to perform 
meaningful statistical analysis were not generated – however, it was considered 
that these data provided reassurance our storage method was appropriate and 
consistent with other workers in this field. 
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Figure 3.4. An investigation of the effects of storage and freeze-thawing of 
bortezomib in K562 cells. Viable cell count is x104/mL. Points and error bars 
indicate mean±SEM with adjoining line of best fit. Conditions compared were 
bortezomib used within 24h of reconstitution (-■-), 24h storage at -20°C (- ◊-), 2m 
storage at -20°C (- ○-) and 3m storage at 4°C (- □-). 
 
3.1.3 Bortezomib wash-out 
Bortezomib is a reversible proteasome inhibitor. Data generated from in vivo 
exposure indicates that peak plasma levels may be acheived in the PB at 1h 
following administration with associated maximal proteasome inhibition (discussed 
in section 1.9.6). The exposure time required to achieve irreversible cell death may 
therefore be short. To investigate this drug wash-out experiments were performed 
with K562 cells as described in 2.4.2. Cells were exposed to drug containing 
medium for the stated times with the final analysis at 72h (Figure 3.5). The data 
show that in our in vitro system between 12 and 24h exposure is required to 
induce significant cell death, hence a minimum of 24h exposure was used in our 
experiments. The limited effect of short exposure times may reflect the reversible 
nature of proteasome inhibition with bortezomib. In addition, drug containing 
medium was incubated in cell culture conditions (37ºC with 5% CO2) for up to 72h 
prior to treatment of K562 cells. This caused no apparent reduction in efficacy for 
inducing cell death (data not shown here). This was interpreted as an indication 
that viable drug may be present in the cell culture media for up to 72h. However, 
metabolism of bortezomib by exposed K562 cells is not assessed by this method. 
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Figure 3.5. Effects of time limited exposure to bortezomib in K562 cells. All cells 
analysed by cell counting and flow cytometry at 72h after exposure to bortezomib 
containing media for set times from initiation of experiment. No wash out (-□-), 
wash out at 1h (-■-), 6h (-▲-), 24h (-▼-) and 48h (-●-) exposure. Viable cell count 
is x104cells/mL. Points indicate mean values for experiment with adjoining lines. 
 
3.1.4 Detection of active Caspase-3 
Active caspase-3 is a key regulator and a recognised marker of cells undergoing 
apoptosis. Cell viability experiments with annexin-V and 7-AAD staining provided 
an indication that bortezomib induced apoptosis in BCR-ABL+ cell lines. 
Demonstration of the presence of active caspase-3 was considered important to 
verify this by an alternative experimental technique. BCR-ABL+ Ba/F3 cells were 
treated with 20nM bortezomib for 24h, a viable cell count taken and then cells 
treated as described in 2.4.3 to determine the presence of active caspase-3 
(Figure 3.6). For all BCR-ABL mutants a significant change in detectable active 
caspase-3 was shown when compared to the untreated control populations, 
though there was no statistically significant difference between the 4 transfectants 
in either viable cell count or % of cells with active caspase-3. These findings 
confirm that bortezomib induces apoptosis irrespective of BCR-ABL mutation 
status and is consistent with published work in other cancer cell lines (3, 9, 148). 
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Figure 3.6. Percentage of BCR-ABL+ Ba/F3 cells with active caspases-3 
detectable by flow cytometry. A comparison is made between untreated cells (0) 
and those exposed to 20nM bortezomib (20) for 24h. There was no significant 
difference (n.s.) between Ba/F3-p210 and the mutated BCR-ABL forms following 
drug exposure. 
 
3.1.5 Thymidine incorporation 
There is published data produced by various methods which show that bortezomib 
is antiproliferative in cancer cell lines (1, 6, 9). IM, dasatinib and nilotinib have a 
significant antiproliferative effect in BCR-ABL+ cells and this is likely to be relevant 
in their efficacy for treating CML a disease characterised by uncontrolled cell 
proliferation. A method by which incorporation of 3H-thymidine is measured was 
utilised to establish whether bortezomib influenced cell proliferation. K562 and 
BCR-ABL+ Ba/F3 cells were cultured with defined concentrations of bortezomib. It 
was seen that drug exposure was associated with reduced incorporation of 3H-
thymidine, consistent with reduced proliferation when compared to the untreated 
cells. Using this method (2.4.4) and at 48h drug exposure the concentration 
required to inhibit proliferation by 50% in comparison to untreated cells (IC50) was 
estimated at 8.4nM (K562) and 8.7nM (Ba/F3-M351T). As a consequence of 
technical problems with the cell harvester this assay became increasingly 
unreliable during the course of the project and so was used only in the preliminary 
experiments. 
 79 
 
0 5 10 15 20
0
25
50
75
100
bortezomib (nM)
Th
ym
id
in
e
 
in
c
o
rp
o
ra
tio
n
 
(%
)
 
Figure 3.7. A reduction in proliferation with K562 cells (··X··) and Ba/F3–M351T (--
○--) cells exposed to bortezomib for 48h as measured by incorporation of 3H-
thymidine. Points and error bars indicate mean±SEM with line of best fit.  
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Aim 2 Proteasome activity in BCR-ABL+ cell lines 
 
It has been demonstrated that cancer cells have abnormally high levels of 
proteasome expression and activity (133). Furthermore, there is evidence from cell 
line work and samples from patients with CML that the presence of BCR-ABL is 
associated with increased proteasome activity, as measured using a fluorescent 
substrate based assay (2). We aimed to demonstrate detectable proteasome 
activity in the BCR-ABL+ cell lines which are susceptible to the apoptotic and 
antiproliferative effects of bortezomib and to assess the impact on this activity of 
exposure to PI. 
 
3.2 Proteasome activity is detectable in BCR-ABL+ cell lines and in Ba/F3 
cells, is variable between different BCR-ABL mutations and is inhibited by 
bortezomib.  
 
3.2.1 Baseline proteasome activity in Ba/F3 mutants 
A fluorescence based assay (2.6) was used to measure the proteasome activity of 
Ba/F3 cells. A linear rise in AFU was seen, consistent with AMC release 
representing proteasome subunit enzyme activity (Figure 3.8 and 3.9). 
Interestingly, the basal proteasome activity appeared to vary between the Ba/F3 
BCR-ABL+ mutants when considering PG and CT-L activity. Statistical 
significance was achieved in PG activity (p<0.01 (H396P), p=0.013 (M351T)) and 
CT-L activity (p=0.047 (T315I), p=0.045 (H396P), p=0.038 (M351T)).  
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Figure 3.8 Detectable proteasome subunit activity in Ba/F3-p210 (■) and K562 (■) 
cells expressed in AFU/min (mean±SEM). PG (post-glutamyl hydrolyzing), CT-L 
(chymotrypsin-like) and T-L (trypsin-like) activities are represented. 
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Figure 3.9 Proteasome activity in Ba/F3-T315I (■), Ba/F3-H396P (■) and Ba/F3-
M351T (■) expressed in AFU/min (mean±SEM) as a ratio compared to Ba/F3-
p210.  PG (post-glutamyl hydrolyzing), CT-L (chymotrypsin-like) and T-L (trypsin-
like) activities are represented. * indicates statistical significance. 
 
3.2.2 Effect of bortezomib treatment on proteasome subunit activity 
Ba/F3 cells were cultured in the presence of 20nM bortezomib for 24h and 
proteasome subunit activity assessed (as described 3.2.1). This concentration was 
chosen to induce significant apoptosis and impair proliferation. The effect of 
bortezomib of the subunit activities in the different BCR-ABL+ Ba/F3 cell types was 
similar and so data from the 4 types was pooled and is shown in Figure 3.10. 
Significant residual proteasome subunit activity remained despite significant 
effects on viability (figure 3.3). This has been seen by others in HeLa cells where 
high concentrations of bortezomib (500nM) were required to achieve >90% 
inhibition of CT-L activity (189). Of interest is that bortezomib inhibited all 3 subunit 
activities, despite the purported CT-L selectivity of this drug. These results we 
show are in concordance with published data with bortezomib treatment of cell 
lines (10-500nM) and using a similar technique reveals inhibition of T-L (10->90%) 
and PG (20-90%) activities(186, 189).  
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Figure 3.10 Effect of bortezomib 20nM on proteasome subunit activity in BCR-
ABL+ Ba/F3 cells. Results shown represent % AFU/min in comparison to 
untreated cells (of same cell type). Pooled data is shown from Ba/F3-p210, -
H396P, -M351T and -T315I cells and expressed as mean±SEM. 
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Aim 3 Effect of PI on BCR-ABL activity in BCR-ABL+ cell lines 
 
Bortezomib has antiproliferative and apoptotic effects in BCR-ABL+ cells and this 
activity is associated with a reduction in proteasome activity. The deregulated 
tyrosine kinase activity of BCR-ABL is associated with the malignant phenotype 
and characterised by increased proliferation and cell survival (described in section 
1.5). The effect of proteasome inhibition on BCR-ABL activity is therefore of 
interest. There is also particular relevance to the later aim of establishing whether 
there is potential benefit in combining bortezomib with TKI. 
 
3.3 Bortezomib reduces BCR-ABL activity in BCR-ABL+ cell lines 
 
3.3.1 Effect of bortezomib treatment on BCR-ABL activity in K562 cells 
K562 cells were exposed to bortezomib (2.5 to 20nM) or dasatinib (150nM) for 24h 
and then lysates prepared for Western blot analysis (2.4.2). Following SDS-PAGE 
electrophoresis and electrophoretic transfer onto a nitrocellulose membrane, the 
samples were probed with anti-pCrkl and anti-pan-actin. Crkl is an adaptor protein 
which plays an important role in BCR-ABL mediated signal transduction. The 
detection of pCrkl is an established method for demonstrating BCR-ABL activity. 
Crkl is tyrosine phosphorylated by BCR-ABL (190) and this phosphorylation 
correlates well with the level of BCR-ABL expression (191). Furthermore, the 
reduction in pCrkl as a consequence of BCR-ABL inhibition has been 
demonstrated with TKI therapy in CD34+ CML cells (192). By this technique we 
demonstrated that in K562 cells bortezomib exposure appeared to be associated 
with a decrease in BCR-ABL activity. BCR-ABL activity was effectively reduced 
with exposure to 150nM dasatinib for 24h for comparison (Figure 3.11). 
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Figure 3.11. Treatment of K562 cells for 48h. Membrane probed with anti-pCrkl 
and anti-pan actin. Additional second band in lower membrane is due to residual 
anti-pCrkl binding as a consequence of inadequate membrane stripping of an avid 
antibody. Dasatinib 150nM (das) in comparison to stated nM concentrations of 
bortezomib. Densitometry (expressed as % of ND control and relative to actin 
loading) das 24% bortezomib 1nM 109% 2.5nM 81% 5nM 21% 10nM 22% 20nM 
20%. 
pCrkl 
pan-
actin 
ND    das      1     2.5      5       10      20 
    Bortezomib (nM) 
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Aim 4 Effect of PI on viability and proliferation of CML patient samples 
including the quiescent subpopulation 
 
Cell line work established that bortezomib was antiproliferative and induced 
apoptosis in BCR-ABL+ cell lines with an associated decrease in BCR-ABL and 
proteasome activity. By use of similar techniques, this work was extended to 
investigate effects on BCR-ABL+ CD34+ cells taken at diagnosis from patients 
with CP CML.  
 
3.4 Bortezomib is antiproliferative and induces apoptosis in CML CD34+ 
patient samples  
 
CML CD34+ cells were cultured in SFM+5GF in the presence and absence of 
bortezomib. At each time point the viable cell count and percentage of apoptotic 
cells were calculated (as described 2.4.1 and 2.4.2). The effect of bortezomib did 
not vary significantly between different patient samples as is seen in data 
generated from initial experiments (Figure 3.12A) and the results were therefore 
pooled with mean±SEM established and dose-response curves predicted (Figure 
3.12B). The LD50 was 8.8±0.7nM (n=5) at 24h, 7.6±0.4nM (n=3) at 48h and 
5.7±1.6nM (n=7) at 72h. The effect of bortezomib on the expansion of the CML 
CD34+ cell population in SFM+5GF can be seen in Figure 3.12C.  
 
CML CD34+ (n=1) were also analysed for the effects of bortezomib on cell viability 
in SFM-5GF with the LD50 7.89±1.07nM (24h), 3.54±1.41 (48h) and 4.13±0.18nM 
(72h).  
 
 
Figure 3.12 (A) A comparison of the effect of 24h bortezomib exposure on the 
viable cell count of 3 different CD34+ CML patient samples cultured in SFM+5GF. 
CML217 (■), CML218 (■) and CML228 (□). Based on estimations from the curves 
of best fit the LD50 was 8.4nM (CML217), 9.2nM (CML218) and 10.4nM (CML228). 
(B) The effect of 24h bortezomib exposure on the viable cell count and % cells 
undergoing apoptosis in 5 different CD34+ CML samples cultured in SFM+5GF. □ 
viable cell count and ▲ % cells undergoing apoptosis with broken lines indicating 
predicted curves of best fit. (C) CD34+ CML samples (n=3) were seeded at 
2.5x105cells/mL and then analysed for viable cell count and apoptosis at 24, 48 
and 72h. Points indicate untreated cells (-□-), 4nM, (-▲-), 8nM (-▼-) and 16nM (-
●-) bortezomib with adjoining lines. 
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   Figure 3.12 
 
Total CD34+ from 4 patients were taken and examined in duplicate on 3 separate 
occasions for the presence of intracellular active caspase-3 when cultured with 10 
and 20nM bortezomib. It was seen that there was a significantly reduced viable 
cell count in all these 3 samples with the addition of bortezomib at these 
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concentrations, or dasatinib 150nM.  There was a trend to an increase in 
detectable intracellular activated caspase-3 when exposed to bortezomib 
(reaching statistical significance with 20nM) – this was not the case with the 
dasatinib treated samples (Figure 3.13).  
 
A      B 
 
Figure 3.13. (A) Total CD34+ cells (n=4) cultured for 24h in SFM+5GF with viable 
cell counts taken and then the fold increase in population compared between 
untreated cells (no drug) and those treated with bortezomib (10nM or 20nM) and 
dasatinib 150nM. (B)These samples were then analysed by flow cytometry to 
assess the % cells with detectable active caspase-3. 
 
An important substrate of caspase-3 is poly(ADP-ribose) polymerase (PARP). This 
protein plays a role in DNA repair and is cleaved to detectable fragments by 
caspases. The detection of these fragments is therefore a useful marker for 
caspase activity and apoptosis. Here we showed the cleavage of PARP in cell 
lysates following incubation of CML CD34+ cells for 24h with bortezomib (Figure 
3.14). The PARP antibody used detects full-length PARP (116kDa) and the large 
(89kDa) cleavage fragment. Dasatinib 150nM did not induce significant apoptosis 
at this time point. 
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Figure 3.14. CML CD34+ cells treated with 10 or 20nM of bortezomib or 150nM 
dasatinib (das) and compared to untreated (ND) cells. All cells were cultured in 
SFM+5GF for 24h prior to preparation of cell lysates for Western blotting. The 
upper band represents full length PARP and the lower the 89kDa cleavage 
fragment. Membranes were probed with anti pan-actin to assess protein loading.  
 
  ND     10      20   das 
PARP 
pan-actin 
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Aim 5 Effect of PI on BCR-ABL activity in CML patient samples 
Aim 6 Proteasome activity in CML patient samples 
 
These aims are considered together. Western blotting using a variety of different 
primary antibody incubations enabled both questions to be considered 
simultaneously in these experiments. 
 
3.5 Bortezomib inhibits proteasome activity but does not affect BCR-ABL 
activity in CML CD34+ patient samples 
 
The fluorescent substrate assay was not suitable for use in patient samples due to 
the large number of cells required (1x107) to provide the required 50-100µg lysate 
per replicate. Preliminary experiments using fewer K562 and Ba/F3 cells (0.1-
0.5x107cells) were unsuccessful in yielding consistent, detectable proteasome 
activity. Therefore, indirect measures of proteasomal inhibition were investigated. 
Substrates are targeted for proteasomal degradation by the attachment of ubiquitin 
units in the form of a polyubiquitin chain. Therefore, the accumulation of 
polyubiquitinated proteins, shown here by Western blot, is an accepted marker of 
proteasome inhibition. This method was applied to CML CD34+ cells following 24h 
exposure to bortezomib (Figure 3.15A). This effect was not seen with dasatinib 
150nM (Figure 3.16). We used the presence of the adaptor protein pCrkl as a 
specific marker of BCR-ABL kinase activity as described in 3.1.3. The detection of 
pCrkl by Western blot following 24 and 48h bortezomib and 24h dasatinib 
treatment is seen in Figure 3.15B. Despite significant effects on cell viability there 
was minimal effect on BCR-ABL activity with either 10nM bortezomib (97±23%) or 
20nM bortezomib (73±5%) in contrast to dasatinib 150nM (23±10%) - results from 
24h drug exposure, expressed as densitometry readings (n=2) using the ratio of 
pCrkl:actin bands shown as a percentage of the untreated sample (mean±SD).  
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Figure 3.15 (A) Separate CML CD34+ samples (X, Y) were treated for 24h with 
bortezomib 10 or 20nM (10, 20) and compared with an untreated control (ND). 
Accumulation of poly-ubiquitinated proteins of varying molecular weights was 
seen. Protein loading was assessed using anti-actin antibody. Residual BCR-ABL 
activity represented by the pCrkl band can be seen in all samples. (B) A 
representative CML CD34+ sample treated with bortezomib 10 or 20nM (10, 20) or 
dasatinib 150nM (das) for 24h and 48h and compared with untreated control (ND). 
The presence of the pCrkl band demonstrates the significant residual BCR-ABL 
kinase activity in PI treated samples compared with the abrogated activity in the 
das treated sample. 
 
 
The cyclin dependent kinase inhibitor p57kip2 was also selected as a marker of 
proteasome inhibition. As described in the introduction, the CDKi p27kip1 and 
p57kip2 are substrates for the proteasome and accumulation with PI exposure in 
cell lines has been demonstrated. We used an anti-p27kip1 antibody which has dual 
specificity for p27kip1 and p57kip2. We failed to demonstrate a clear band at the 
pan-actin 
pCrkl 
ND    10      20    das    ND     10     20 
24h 48h 
pan-actin 
ND     10      20      ND    10      20  
pCrkl 
X Y 
ubiquitin 
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expected molecular weight for p27kip1 despite varying the quantity of lysate (10-
20µg per well) and by use of a 15% gel. However a clear band was seen 
consistent with the 57kDa protein p57kip2 with relatively increased protein levels 
detected in those cells treated with 20nM bortezomib, consistent with proteasome 
inhibition (Figure 3.16). 
 
 
 
 
Figure 3.16 CML CD34+ cells cultured in SFM+5GF and treated with dasatinib 
150nM (das) or bortezomib at stated concentrations (2.5nM to 20nM) for 24h and 
compared with untreated cells (ND). Lysates were prepared for Western blot and 
membranes probed with anti-p27kip1, anti-ubiquitin and anti-pan-actin.  
p57kip2 
 
 
 
 
ubiquitin 
 
 
 
 
 
 
 
 
 
 
 
 
pan-actin 
ND  das  2.5   5   10   20 
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Aim 7 Effect of PI on primitive cells from CML patient samples 
Aim 8 Effect of PI on non-CML patient samples  
 
Patients with CML on TKI harbour a primitive population of cells, enriched within 
the CD34+38- fraction, which are resistant to TKI exposure. We aimed to establish 
whether these cells were sensitive to the effects of bortezomib and if so, whether 
there was any difference in sensitivity in comparison to a similar sub-population of 
cells derived from patients without CML. Proliferation assays using CFSE staining 
were also performed to achieve Aim 7. By these means it was possible to 
determine drug effects within distinct subpopulations separated by division number 
and therefore allowed assessment of the effect of bortezomib on quiescent cells. 
 
3.6 Bortezomib induces apoptosis in the CML CD34+38- population, though 
with minimal selectivity for leukaemic stem cells 
 
Previous work has demonstrated the relative insensitivity of early haematopoietic 
progenitor cells to TKI therapy. We used a process of cell sorting to isolate the 
CD34+38- fraction of the CD34+ CML patient samples. It is within this population 
that primitive progenitor cells are enriched as has been shown in both the normal 
marrow (37) and leukaemia (41, 42). CD34+38- cells were enriched from 3 CML 
CD34+ patient samples. Samples were cultured in SFM+5GF with bortezomib and 
viable cell counts taken at 24h of drug exposure (Figure 3.17A). Results were 
compared to untreated controls. The LD50 at 24h was 8.93±1.42nM. This was 
similar to the LD50 of the unsorted CML CD34+ cells (section 3.4). To illustrate this 
consistent effect on different cell populations, CML CD34+38- and CML 
CD34+38+ cells (n=3) were exposed to bortezomib for 24h and effects compared 
(Figure 3.17B). CD34+38+ enriched cells represent a relatively more mature and 
proliferating population of CML cells. LD50 values of 8.18±0.64nM for CD34+38+ 
cells were obtained and this was not significantly different from the CD34+38- 
population.  
 
Similar experiments were performed in duplicate using 2 non-CML samples. At 
24h drug exposure, the LD50 was 10.18±1.85nM (Figure 3.17C), which was not 
significantly higher than for CML CD34+38- cells. 
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Figure 3.17 (A) CD34+38- (n=3) cells were cultured in SFM+5GF and analysed at 
24h. The viable cell count (□) is expressed as a percentage of untreated (cell 
count %). The percentage of cells staining positive for 7-AAD (▲) is expressed on 
the y–axis (% cells apoptotic). (B) The effect of bortezomib on CD34+38-(■) and 
CD34+38+ cells (□) (n=3) was compared. The viable cell count is expressed as in 
(A). (C) CD34+38- (n=2) cells from non-CML samples were cultured in SFM+5GF 
and analysed at 24h. The viable cell count (□) and % cells apoptotic (▲) are 
derived as in (A). All results represent mean±SEM with predicted dose-response 
curves.  
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3.7 Bortezomib is antiproliferative in CML CD34+ patient cells 
 
The effect of bortezomib on differentiation and division of CD34+ CML patient 
samples cultured in SFM+5GF was assessed with CFSE and flow cytometry 
(2.4.5). A comparison of the effect of dasatinib 150nM or bortezomib 20nM with 
untreated cells is shown in Figure 3.18A. Here 3 control groups were used: 
CFSE-, showing no fluorescence on the CFSE-channel (FL1-H); CFSE+ cells 
exposed to demecolcine to arrest cell division (undivided, CFSEMAX); and CFSE+ 
cells exposed to no drug (untreated). In the analysis only viable cells (based on 
exclusion of PIo) were examined. For each sample a similar number of events 
(1x104) from each sample were counted therefore cell numbers (“Counts” in 
figures 3.18A and B) do not reflect the total number of residual viable cells for 
each condition. This data is examined in later figures. With 72h culture, untreated 
viable cells underwent up to 6 divisions, however cells exposed to greater than 
5nM of bortezomib underwent fewer divisions (Figure 3.18B). Exposure to 2.5nM 
bortezomib over-lay that of untreated cells (not shown). The majority of cells 
exposed to 20nM bortezomib, the maximum dose used in these experiments, 
failed to divide and the histogram (CFSE staining intensity, cell number) was seen 
to overlay the peak intensity of the demecolcine undivided control (Figure 3.18A 
and B). Consistent with published data, cells exposed to 150nM dasatinib 
underwent fewer divisions when compared to the untreated controls (reference (4) 
and Figure 3.18A). Mean data generated from 2 different CD34+ CML samples 
were analysed in Figure 3.19 and demonstrate the percentage of viable cells in 
each division peak. 
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Figure 3.18. Representative plots from CD34+ CML patient sample cultured for 
72h in SFM+5GF following CFSE exposure. (A) ▬ CFSE-, ▬ demecolcine, ▬ 
untreated, ▬ dasatinib 150nM and ▬ bortezomib 20nM. (B) ▬ CFSE-, ▬ 
demecolcine, ▬ untreated, ▬ bortezomib 5nM, ▬ bortezomib 10nM and ▬ 
bortezomib 20nM. In (A) and (B) FL1-H (x-axis) indicates fluorescence intensity of 
CFSE staining and Counts (y-axis) the number of viable cells (based on PIo 
staining). The numbers above graph (A) indicate number of cell divisions each 
population has progressed through. 
6     5     4      3     2     1     0 
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Figure 3.19 CFSE stained cells cultured for 72h in SFM+5GF with no drug (█) 
dasatinib 150nM (█) or bortezomib 20nM (█). The percentage (not total number) 
of viable cells in each sample from each division peak is seen from undivided (0 – 
right) to 6 (left) divisions. Error bars indicate mean±SEM.  
 
The number of cells at each division in the different treatment groups was 
assessed as described in 2.4.5.4 with data shown in Table 3.2. Expansion of the 
CFSE+ cell population in SFM+5GF and the absence of drug was similar to that 
published previously (mean 3.77 versus 3.8 (60)). The percentage recovery 
indicates that fewer cells were surviving in the bortezomib and dasatinib treated 
arms relative to untreated cells – though the percentage recovery considered low 
in the untreated arm, presumably a result of commitment to death in cells counted 
as viable at day 1. Of interest is that the apparent antiproliferative effect of both 
bortezomib 20nM and dasatinib 150nM results in relatively more viable quiescent 
cells being detected in the sample after 72h culture (Table 3.2). The effect of 
bortezomib 10nM does not consistently produce this effect (Figure 3.20). 
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Table 3.2. CFSE data generated from 3 CML CD34+ samples analysed at 72h. 
Total CD34+ cells undivided CD34+ cells drug 
recovery 
(%) 
recovery 
relative to 
ND (%) 
viable cells  
(%) 
recovery of 
input (%) 
recovery 
relative to 
ND (%) 
      
ND 58.05 100 0.74 11.99 100 
B10 9.25 15.93 4.79 3.59 30 
B20 3.65 6.28 3.96 1.58 13.2 
DAS 29.69 51.15 3.05 18 150.1 
      
ND 33.05 100 0.83 3.32 100 
B5 26.39 79.5 1.35 4.3 115.1 
B10 11.08 33.52 7.66 3.82 110.2 
B20 11.94 36.14 44.35 3.66 290.4 
DAS 24.89 75.33 2.56 9.64 124.1 
      
ND 36.17 100 1.73 5.2 100 
B5 30 82.93 1.79 4.24 81.5 
B10 11.82 32.67 6.7 3.19 61.3 
B20 10.73 29.66 38.07 7.25 139.4 
DAS 15.19 41.99 4.25 3.19 61.3 
      
Results from 3 different samples are shown CML232 (█), CML194 (█) and 
CML166 (█). All samples were cultured for 72h in SFM+5GF with (bortezomib (B) 
at 5, 10 or 20nM or dasatinib (DAS) 150nM) or without (ND) drug exposure. 
Recovery refers to a calculation based on the viable cell count and the percentage 
of cells in each division peak (from CFSE staining) which estimated the original 
number of undivided cells from which these populations must have arisen. For 
total CD34+ and undivided CD34+ (i.e. CFSEMAX) a comparison was made to the 
untreated (ND) control (relative to ND columns). The percentage of viable cells 
which are undivided is also shown.  
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Figure 3.20. (A) Recovery of all CD34+ cells and (B) undivided (CFSEMAX) CD34+ 
CML cells displayed as a percentage of the untreated control with comparison 
between bortezomib 10nM and Dasatinib 150nM. For both graphs, CML194 (▲) 
CML166 (▼) and CML 232 (■). 
 
With evidence of cell division (by CFSE staining intensity) there was an associated 
reduction in the percentage of CD34+ cells consistent with the loss of CD34 
expression associated with myeloid maturation (Figure 3.21). In dasatinib treated 
cells there was a trend for the surviving cells at each division peak to have 
relatively less CD34+ expression. This is in contrast to bortezomib treated cells 
where the opposite was seen. In the context of the results seen in Table 3.2 it 
appears that surviving cells have undergone fewer divisions and are of a less 
mature phenotype. This phenomenon has been noted by others using CD34+CML 
cells cultured in SFM-5GF (60).  
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Figure 3.21 CD34+ CML samples (n=2) exposed to CFSE and cultured in 
SFM+5GF for 72h. Division number represents the number of divisions each cell 
population has undergone and is based on CFSE staining intensity, % cells 
CD34+ is the % of viable CD34+ cells (based on PI staining) of that CFSE 
intensity. -■- untreated, -×- dasatinib 150nM and -▼- bortezomib 20nM. Points 
indicate mean±SD with adjoining lines. 
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Aim 9 The potential synergistic effect of PI and TKI on viability and 
proliferation of BCR-ABL+ cell lines and CML patient samples 
 
The current trend in the clinical use of bortezomib is for use in combination with 
other therapies. This is particularly appealing in the setting of this project as the 
results of Aim 8 indicate toxicity to normal cells. Combination therapies are 
established as a mechanism of increasing toxicity to abnormal cells, through 
targeting multiple pathways or different elements of similar pathways with the 
associated benefit of potentially achieving similar effects with reduced individual 
drug exposure. We aimed to investigate the novel combination of bortezomib with 
a TKI. Dasatinib was selected as a model TKI due to the high levels of BCR-ABL 
inhibition that are recorded with clinically achievable doses. 
 
3.8 Dasatinib and bortezomib act synergistically against CML CD34+ cells  
 
Calcusyn® is a software package designed to estimate synergy between 2 drugs 
used together at a fixed ratio of concentrations. The sigmoidal dose-effect curve is 
converted through a logarithmic derivation to a linear graph (Equation 2.2 and 
2.3). Data derived from individual drugs can then be compared to the drug 
combination (which is considered as a 3rd drug) by the CI (Equation 2.4) which is 
a measure of synergy/antagonism. 
 
CML CD34+ cells (n=3) were cultured in SFM+5GF and exposed simultaneously 
to a combination of bortezomib:dasatinib at different fixed ratios (2.5:1 to 10:1) . 
Cell counts and flow cytometry were performed at 72h to assess the effects on cell 
viability. This time point was chosen as preliminary experiments demonstrated that 
earlier time points underestimated cell death induced by dasatinib. The data were 
analysed using Calcusyn®. Figure 3.22 illustrates a dose-effect profile of 
bortezomib, dasatinib and the drug combination (2.5:1).  
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Figure 3.22 Dose effect profile for dasatinib (▬), bortezomib (▬) and 2.5:1 
combination (▬). Effect (x-axis) is fa as calculated in Equation 2.3 and Dose (y-
axis) the concentration of drug (nM) and expressed as bortezomib concentration in 
the drug combination.  
 
This data may also be viewed as an isobologram where the linear profile of 
defined effects (LD50, LD75 and LD90) is seen with the corresponding data from the 
drug combination experiments (Figure 3.23). Data fell consistently below the line 
of effect and so indicated synergy.   
 
 
Figure 3.23 Isobologram of fixed additive effects at LD50 (▬), LD75 (▬) and LD90 
(▬). Experimental data from ratio of 2:5:1 is shown corresponding to these effects 
(X, X and X) respectively.  
 
Synergy was demonstrated in these samples at both drug ratios and at end points 
including LD50, LD75 and LD90 (Table 3.3). 
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Table 3.3 Combination indices for bortezomib and dasatinib used simultaneously 
in CML patient samples. 
Combination index Ratio 
LD50 LD75 LD90 
r-values 
     
2.5:1 0.67±0.16 0.54±0.16 0.53±0.21 0.85-0.99 
5:1 0.78±0.12 0.66±0.13 0.64±0.16 0.90-0.98 
10:1* 0.87±0.25 0.75±0.22 0.69±0.22 0.93-0.94 
     
Ratio described as bortezomib:dasatinib, synergism (█), moderate synergism (█) 
and slight synergism (█) as defined by Chou TC (185).  
*For 10:1 n=2, for 2.5:1 and 5:1 n=3. 
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4. DISCUSSION 
 
4.1. Overview 
The current recommended treatment for the majority of patients with CP CML is 
IM. There is accumulating evidence that the majority of patients respond to this 
drug and achieve the therapeutic milestone of a CCyR. However TKI induce a 
state of MRD and many patients continue to have detectable BCR-ABL transcripts. 
In addition, MRD may persist in those with undetectable BCR-ABL transcripts, with 
the “undetectable” results a reflection of the limitation of the assay rather than true 
CML eradication. There may be a subpopulation of patients treated with IM with 
undetectable BCR-ABL transcripts who have achieved disease eradication. This 
question was addressed in the Stop Imatinib (STIM) study, with preliminary results 
presented recently. Here it was seen that 15 of 34 patients with undetectable 
BCR-ABL who had discontinued IM for ≥6m showed no evidence of disease 
relapse. Of these 5 patients had received IM therapy alone. However follow-up is 
relatively short and the recommendation remains that patients should be treated 
indefinitely (98).  
 
For the majority if IM treated patients, the source of MRD is presumed to be the 
population of Ph+HSC. These cells are relatively insensitive to TKI. Furthermore 
the development of TKI-resistant BCR-ABL mutations is a cause of primary and 
secondary treatment failure. In particular T315I is resistant to all available TKI and 
there is concern that selection pressure may result in this mutation becoming more 
prevalent.  The proteasome is an attractive target for cancer therapy and there has 
been expansion of the clinical use of bortezomib, to date the only licensed PI. In 
this study we provide evidence that this drug has potential as a therapy to target 
cells expressing BCR-ABL including T315I mutated forms. There is also evidence 
that the Ph+HSC may be susceptible to the apoptotic effect of this drug. Concerns 
over the relatively non-selective action of bortezomib may potentially be overcome 
by use in combination with TKI. This would be in line with the majority of clinical 
studies of bortezomib where it is now seldom used as monotherapy. 
 
4.2 Targeting BCR-ABL+ cell lines, including mutant forms 
We demonstrate that BCR-ABL+ cell lines (K562 and Ba/F3-p210) are subject to 
reduced proliferation and increased apoptosis when exposed to bortezomib for 
greater than 12h (Figure 3.5). Different techniques were used to establish an LD50 
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in K562 and included cell counting by vital dye exclusion (LD50 5.6nM at 48h 
Figure 3.1), cell counting combined with flow cytometry with annexin-V and 7-AAD 
staining (LD50 6nM at 48h Figure 3.2) and 3H-thymidine proliferation assays (IC50 
8.4 Figure 3.7). Ba/F3 cells transduced and expressing p210 and mutated BCR-
ABL were assessed following bortezomib exposure with cell counting and flow 
cytometry. An LD50 of between 6.3 and 11.3nM at 24h was established, with no 
significant difference between p210 and the 3 different BCR-ABL mutants (H396P, 
M351T and T315I). These cells were assessed at this early time point as drug 
wash-out experiments indicated that longer exposure was probably not necessary. 
We confirmed by flow cytometry for activated caspase-3 that apoptosis was 
induced by bortezomib in Ba/F3 cells (Figure 3.6) a result predicted by the 
movement of cell populations through the annexin-V and 7-AAD quadrants with 
continuous drug exposure. 
 
These results may be compared to published work previously demonstrating that 
BCR-ABL+ cell lines are susceptible to the antiproliferative and antiapoptotic 
effects of PI. Servida et al. exposed a range of cell lines to the PI bortezomib and 
Z-Ile-Glu(OtBu)-Ala-Leucinal (PSI) – though in this study the LD50 for bortezomib 
in IM-sensitive K562 was 110nM at 48h (by PIo staining and flow cytometry) (8). 
These results are at variance with others using flow cytometry and annexin-V 
staining and showing an LD50 of 32nM with bortezomib in K562 at 48h (3). A 
separate group examined KBM-5 and -7 (as with K562 both lines derived from 
human BC CML) which were either IM sensitive or IM resistant. Assays of cell 
proliferation demonstrated an IC50 between 10-15nM at 48h with identical dose-
response curves between the IM-resistant and sensitive cells lines. This inhibition 
was correlated with accumulation of cells in G2M phase, induction of caspase-3 
and an inhibition of NFkB activity by EMSA (1).  
 
It is difficult to explain why our results with K562 are at variance with Servida et al. 
as a similar technique was adopted. It is unlikely to be due to storage artefact of 
bortezomib as we have demonstrated that freeze-thawing does not appear to 
enhance the potency of drug effect in the assays used. In addition in all cases the 
bortezomib was obtained directly from the manufacturers. 
 
Our results add evidence to those published previously that IM-resistance does 
not appear to influence bortezomib sensitivity. What is added by our work is that 
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specific mutations of BCR-ABL are equally sensitive to apoptosis, including the 
T315I mutation. This is clearly of clinical relevance as there is no current licensed 
therapy available for these patients other than conventional treatments such as 
hydroxycarbamide or busulphan which will achieve only haematological 
responses. Haematopoietic stem cell transplantation is a further option though is 
limited by the toxicity of conditioning regimes – of particular concern in CML which 
is predominantly a disease of the elderly. The results with bortezomib can be 
compared to those generated with the aurora kinase inhibitor MK-0457 (VX680) 
and homoharringtonine (HHT). The aurora kinases are key regulators of mitosis 
and abnormal activity is associated with a number of malignancies including 
leukaemia.  Aurora kinase inhibitors block cell-cycle progression and induce 
apoptosis in BCR-ABL+ cell lines, including the T315I mutant (126, 128).  A series 
of 3 patients with the T315I mutation and treated with MK-0457 showed promising 
early evidence of clinical responses (127)., however clinical trials were 
subsequently stopped due to unacceptable levels of toxicity. HHT is a 
cephalotaxus alkaloid which has previously been shown to have antiproliferative 
effects and induce caspase-3 dependent apoptosis in IM-sensitive and resistant 
BCR-ABL+ cell lines (193). Prior to the introduction of IM, HHT was used in a 
clinical trial for patients with CP CML with 72% CHR and 15% CCyR achieved 
(194). More recently HHT has been used in 17 patients with IM-resistant CML in 
all disease phases. Conventional responses were obtained only in the small 
number of CP patients treated and none were sustained (195). However, of 
particular interest is emerging data that HHT may have a preferential effect on the 
T315I mutant. This comes from 2 clinical trials where patients with IM-resistant 
CML and the confirmed presence of the T315I mutation have been treated with 
HHT. In both trials a rapid fall in T315I BCR-ABL transcripts was reported with 
associated haematological and cytogenetic responses (99, 196).  
 
In addition we performed baseline proteasome activity assays in the K562 and 
Ba/F3 cells and were surprised to document differences in both PG and CT-L 
activity between the Ba/F3 mutants. This reached statistical significance in Ba/F3 
T315I, Ba/F3-H396P and Ba/F3-M351T for CT-L activity and Ba/F3-H396P and 
Ba/F3-M351T for PG activity. This did not translate into differences in susceptibility 
as shown, though there was a trend for the BCR-ABL mutants to be slightly less 
susceptible. Multiple replicates would be required to determine any subtle 
differences – which may not be of clinical consequence. However such data would 
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be interesting and comparable to the apparent enhanced susceptibility of T315I 
mutations to HHT (196). Our findings may also augment data published in this field 
comparing the biology of different BCR-ABL mutants, in particular mutations are 
present in IM-naïve patients which may confer a survival advantage to cells (197). 
There are published data demonstrating that BCR-ABL mutants may have differing 
oncogenicity (by transformation of mouse BM cells) and ABL-kinase activity (by 
global phosphotyrosine assays) with selected data demonstrated in Table 4.1. 
However, there are no data published comparing the proteasome activity of the 
mutants.  
 
Table 4.1 Published data of BCR-ABL mutants 
BCR-ABL 
mutant 
Transforming 
potential 
Kinase activity Reference 
T315I =/↑ ↓ (198, 199) 
H396P ↓ ↓ (198) 
M351T ↓ ↓ (199) 
Activity relative to p210 BCR-ABL with ↓ increased and ↑ decreased activity.  
 
With bortezomib treatment we demonstrate the expected inhibition of CT-L activity. 
Data for the Ba/F3 mutants was pooled as little differences were seen between the 
mutants at the concentration tested (20nM). We also demonstrated some 
reduction in PG and T-L activity. This has been demonstrated by others using this 
technique with bortezomib which is reported to be a relatively selective CT-L PI. 
(186). This may reflect a limitation of the assay for determining specific 
proteasomal subunit activity or illustrate the theory that protein degredation is 
reliant on all active sites and so inhibition of CT-L activity may impair protein 
degradation through other routes (189). We did not assay proteasome activity to 
determine a dose response curve. This has been done previously both in vitro and 
data has been generated from clinical trials. There appears to be a maximally 
tolerated threshold effect at around 80% inhibition where toxicity is significantly 
limiting (177). This may reflect the non-selective nature of proteasome inhibition 
and there may be an exposure level at which all cells will be unable to function and 
so undergo apoptosis. It is reassuring to see that the concentration used here 
(20nM) generated significant apoptosis in Ba/F3 cells however was associated 
with only approximately 40% inhibition of substrate release. This may also indicate 
that bortezomib may have targets other than the proteasome. Though not fully 
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characterised it has been demonstrated that bortezomib targets non-proteasomal 
cellular enzymes including the protease enzymes cathepsin A/G and chymase 
(200).  
 
It has previously been shown by using FDCP-MIX cells transfected with a 
temperature sensitive BCR-ABL construct that BCR-ABL activity is associated with 
an increase in proteasome activity, as measure by release of fluorescent AMC-
bound peptides. The BCR-ABL+ cells were also more susceptible than BCR-ABL- 
cells to apoptosis induced by PI (BzL-LLCOCHO) exposure (2). No clear pathway 
has been established linking the proteasome to BCR-ABL activity. However BCR-
ABL activity has been associated with constitutive NFkB activity, reduced levels of 
CDKi and an altered balance of pro and antiapoptotic mediators – all of which 
involve potential proteasomal substrates. It is possible that the proteasome is 
activated by one or a number of the many molecular pathways activated by BCR-
ABL kinase. We were interested to note that in K562 exposure to bortezomib for 
48h was associated with a reduction in pCrkl in a dose-dependent manner, 
consistent with reduced BCR-ABL activity. This is consistent with results published 
by Soligo et al. where reduced BCR-ABL protein was detected at 48h with 
exposure of K562 to PSI (201). These results contrast with Yan et al. who failed to 
detect any difference in BCR-ABL protein in K562 with 48h exposure to 32nM 
bortezomib. We did not probe for BCR-ABL protein levels and so direct 
comparisons cannot be drawn. It is conceivable that the proteasome may be 
influencing stability and/or activity of proteins downstream of BCR-ABL modulating 
phosphorylation of Crkl though further characterisation of this was considered 
beyond the scope of this project. 
 
4.3 Targeting the CML stem cell 
We have demonstrated that CD34+ selected leukapheresis samples taken from 
patients with CP CML at diagnosis are susceptible to the antiproliferative and 
apoptotic effects of bortezomib. CML CD34+ cells were exposed to bortezomib 
and cultured in SFM+5GF. The LD50 was 8.8±0.7nM (n=5) at 24h, 7.6±0.4nM 
(n=3) at 48h and 5.7±1.6nM (n=7) at 72h. The different patient samples selected 
did not appear to vary in susceptibility to this drug and the absence of growth 
factors did not significantly affect responses. The expansion of CML CD34+ in 
SFM+5GF was impaired in the presence of the drug indicating an additional 
antiproliferative effect. These results are illustrated in Figures 3.12A-C. Evidence 
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for apoptosis was provided by the increase in detectable intracellular activated 
caspase-3 with bortezomib exposure (detected by flow cytometry, Figure 3.13B) 
and the cleavage of PARP (detected by Western blotting, Figure 3.14). The 
concentration of bortezomib required to achieve these results is similar to that 
inhibiting proliferation of human multiple myeloma cells (IC50 2.5-30nM (5)) and 
CD34+ selected human AML samples (IC50 5-10nM at 7d (6)). 
 
We utilised Western blotting to detect the accumulation of polyubiquitinated 
proteins as a marker of proteasome inhibition. This was clearly demonstrated in 
CML CD34+ following 24h exposure to bortezomib though not with TKI therapy 
(Figure 3.15A and 3.16). This time point was chosen for consistency of analysis 
allowing correlation with experiments assessing apoptosis and proliferation – in 
turn based on drug wash-out experiments in cell lines. There is published 
evidence that a much shorter exposure of 1h is required to achieve maximum 
proteasomal inhibition in vivo (168) though the recovery of cells in vitro following 
short exposure may relate to the reversible inhibition associated with bortezomib.  
 
We also demonstrate effects on the CDKi p57kip2 (Figure 3.16). This is consistent 
with an inhibitory effect of PI on cell cycling through the prevention of the 
enhanced removal of CDKi seen in a number of malignancies including CML. PI 
treatment of CML has been associated with increased levels of p27kip1 and p21cip1 
which are both members of the CIP/KIP family which also includes p57kip2 (145, 
147, 148). This is of particular interest as it has been shown that p57kip2 but not 
p27kip1 sensitises cancer cells to apoptosis by mitochondrial translocation resulting 
in loss of MMP and release of cytochrome c with consequent apoptosis (202).  
 
In contrast to the results shown for the K562 cell line, we did not demonstrate 
significant effects on BCR-ABL activity with up to 20nM bortezomib exposure for 
up to 48h. There are a number of potential explanations for these differences. The 
comparison is between an immortalised BC cell line and a CP patient derived 
CD34+ selected product and so there is likely to be inherent differences in the 
balance of intracellular signalling pathways between these samples. It may be that 
longer exposure or higher concentrations of bortezomib are required to achieve 
the effect on BCR-ABL activity seen in K562. However we were interested to note 
significant BCR-ABL activity was detected in CD34+ CML samples at 
concentrations in excess of the LD50 and the derived area-under-the-curve drug 
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exposure in vivo. This would be consistent with the proteasome functioning either 
independently of BCR-ABL or downstream through activated signalling pathways. 
However there are caveats to both of these suggestions – BCR-ABL activity in cell 
lines is associated with increased proteasome activity and effective TKI exposure 
does not result in accumulation of polyubiquitinated proteins as detected by 
Western blot. It may be that BCR-ABL does mediate an increase in proteasome 
activity beyond basal levels. TKI therapy may ameliorate though not obliterate 
proteasome function which may continue at a sufficient rate to clear 
polyubiquitinated proteins. It is also speculated that the accumulation of 
ubiquitinated proteins may be minimised by stimulation of autophagy – a process 
related to proteasomal function which will be discussed. There may be additional 
interactions between BCR-ABL and the proteasome illustrated by work 
investigating molecular chaperones. It has been shown in BCR-ABL+ cell lines 
that BCR-ABL depends on an association with HSP90 to maintain stability. 
Targeting this association with HSP90 inhibitors (including geldanamycin and 17-
AAG) results in increased ubiquitination and proteasomal degradation of BCR-ABL 
(p210 and mutated forms) (107, 109, 110). Proteasome inhibition may therefore 
protect cells against BCR-ABL breakdown. 
 
We next used FACS to isolate the CD34+38- fraction from 3 CD34+ CML patient 
samples. It is within this population that primitive progenitor cells are enriched with 
evidence for this shown in Table 1.1. The LD50 at 24h was 8.93±1.42nM. This was 
similar to that of unsorted CML CD34+ cells and no significant difference was seen 
when comparing relatively primitive CD34+38- cells to more mature and 
proliferative CD34+38+ (Figure 3.17B).  
 
To further assess the effect of bortezomib exposure on the different populations of 
cells we cultured CML CD34+ cells for 72h with CFSE. This provided insight into 
the number of divisions cell populations had undergone in different experimental 
conditions. As demonstrated previously dasatinib exposure was antiproliferative 
(Figure 3.19 and (4)). Bortezomib treatment at concentrations >5nM showed a 
more marked effect and with 20nM exposure, of the remaining few cells surviving, 
the majority had failed to divide with the curve overlying that of the Colcemid® 
control. Furthermore as the cells divided in the presence of bortezomib they 
appeared to maintain a less mature phenotype as evident in the retention of 
CD34+ surface staining. This phenomenon has been noted by others culturing 
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CD34+ CML cells in the absence of exogenous growth factors and may reflect the 
reduced proliferative potential of cells exposed to bortezomib and it is speculated 
that this may reflect a tendency to undergo self-renewal divisions (60).  
 
To determine the numbers of CD34+ viable cells for each division peak we 
performed recovery calculations based on the assumption that cells will divide in a 
balanced manner with 1 cell producing 2 progeny with equal potential for 
replication. We analysed cells exposed to 10nM bortezomib as this was close to 
the LD50 though it is accepted that the sustained drug exposure potentially 
achieved in vivo for this time period with conventional drug dosing is not known. 
We discovered differences between the 3 samples analysed in this way, however 
when assessing recovery from all division peaks with both dasatinib 150nM and 
bortezomib 10nM exposure there was impaired recovery of CD34+ cells – 
consistent with loss of cells presumably through apoptosis. When the undivided 
peak was assessed the differences were more marked, though only small 
numbers of cells contributed to these peaks. Here it was seen in 2 of the 3 
samples examined there was an increase in recovery of undivided (quiescent) 
CD34+ cells with dasatinib (consistent with published data (4)) in contrast to a 
reduction in this cell population with bortezomib 10nM. This is significant as the 
quiescent Ph+CML is thought to contribute to MRD in TKI treated CML. 
Bortezomib appears to have the potential to reduce this population at 
concentrations which may be clinically relevant as demonstrated in an effect on 
FACS sorted CD34+38- cells and from the CFSE data in which cell division was 
tracked. However the cells are not eradicated and the concentration of bortezomib 
may be critical as higher levels appear to be ineffective in targeting the undivided 
cells and retention of CD34+ staining may reflect a stimulus to self-renewal and so 
maintenance of MRD.  
 
4.4 Relative non-selectivity of bortezomib 
The proteasome is found in all eukaryotic cells and plays a vital role in cellular 
functions – including those resulting in proliferation and apoptosis. Inhibition of the 
proteasome is therefore inherently a non-selective strategy to target cancer cells 
and relies on exploiting a difference in proteasome activity levels, a dependence 
on that activity and/or the ability to recover from disruption to protein turnover. We 
analysed 2 FACS sorted CD34+38- non-CML samples and demonstrated that at 
24h drug exposure the LD50  was 10.18±1.85nM - not significantly different to the 
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results obtained for a similar population of CP CML cells (Figure 3.17C). To 
establish any true difference between CML and normal would clearly require more 
replicates, however a limited number of non-CML samples were available for 
analysis in our laboratory. It is interesting to note of the little published in this field 
there is marked variation in results obtained (Table 4.2). The variation may reflect 
a difference in techniques applied, time-points of analysis and cells used as 
representative of “normal” controls. There is no published data assessing the 
effects of bortezomib on the CD34+38- sorted population as shown here. However 
Servida et al have assessed the effects of a different PI on normal primitive HSC. 
They performed LT-CIC assays with 3 normal BM samples at a single 
concentration of PSI chosen as equivalent to the IC50 demonstrated in CML by 
CFU-GM assay. This concentration did not influence colony formation and was 
therefore considered selective for CML (8).  
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Table 4.2 Published effect of bortezomib on normal cells 
Cells Technique IC50/LD50 Timepoint Reference 
PB MNC Thymidine 
incorporation 
>100nM 48h (5) 
 Annexin-V 
staining 
50nM induced 
48±22% 
apoptosis 
48h (9) 
CD34+ BM Annexin-V 
staining 
50nM induced 
5±5.2% 
apoptosis 
18h (9) 
 CFU-GM 11.3nM 14d (8) 
 Thymidine 
incorporation 
<20nM 7d (6) 
 MTT 260-780nM 48h (203) 
The technique applied and the timepoint for analysis is obtained from the relevant 
publication and the IC50 or LD50 quoted where available. Colony forming units 
granulocyte-macrophage (CFU-GM), MTT assay is a conventional proliferation 
assay measuring a colour change of 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) by mitochondrial activity, Peripheral blood 
mononuclear cells (PB MNC) and CD34+ selected bone marrow cells (CD34+ 
BM). 
 
4.5 Combination of bortezomib with dasatinib 
Drug combinations are commonly utilised for cancer therapy and provide a 
mechanism for enhancing the effect of an agent without increased toxicity. 
Bortezomib is now commonly used in combination with other therapies in clinical 
trials and this is perhaps not a surprise when the myriad cellular processes 
potentially affected by this drug are considered. Bortezomib combinations also 
offer a mechanism to minimise the significant toxicity associated with this drug. In 
the APEX trial published in 2005 where patients were treated with the now 
established 1.3mg/m2 on days 1, 4, 8 and 11 in 3-week cycles, 37% discontinued 
treatment as a consequence of side-effects. Most common serious events (grade 
3 or 4 by NCI common toxicity criteria) were thrombocytopaenia, anaemia and 
neutropaenia. Other more common toxicities included gastrointestinal upset 
(diarrhoea, nausea and vomiting in 57%, 57% and 35% of patients respectively) 
and peripheral neuropathy (in 36% of patients).  
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We combined bortezomib with dasatinib. Dasatinib was selected as the most 
potent TKI available in the clinic and therefore would enable maximal inhibition of 
BCR-ABL activity in combination with potent proteasomal inhibition by bortezomib. 
We did not investigate the molecular pathways which may link BCR-ABL activity 
and the proteasome, though we provide evidence that PI does not affect BCR-ABL 
activity and TKI does not significantly affect proteasome activity as evident by 
accumulation of polyubiquitinated proteins. It has been demonstrated previously 
by analysis of RNA transcripts that primitive Ph+HSC (CD34+38-) express 
relatively higher levels of BCR-ABL than more mature CML cells (4). These cells 
may have relatively higher proteasome activity if the association demonstrated in 
cell lines holds true (2). We hypothesised therefore that the proteasome and BCR-
ABL may provide 2 targets and concomitant inhibiton of these would be 
synergistic. Our results in CD34+ cells are consistent with this demonstrating slight 
synergism to synergism seen at fixed ratio combinations of dasatinib and 
bortezomib at clinically relevant concentrations (Table 3.3). We did not assess 
CD34+38- cells or non-CML cells in this way.  
 
Other groups have assessed TKI in combination with PI in CML cells. Gatto et al.  
exposed BC CML cell lines to IM and bortezomib simultaneously at a single 
concentration of bortezomib (11nM) and failed to demonstrate synergy (1). 
Aichberger et al. combined either IM or nilotinib with MG132 in BCR-ABL+ cell 
lines (including K562 and Ba/F3 cells) and assessed by 3H-thymidine incorporation 
for cell proliferation. No data was presented in the paper though it was stated that 
no synergy was seen (155). We are the first to present data where dasatinib has 
been combined with bortezomib in CD34+ CML samples. Different factors may 
contribute to the more positive data generated in this project: dasatinib would be 
expected to induce more potent BCR-ABL inhibition than IM or nilotinib; and we 
assessed untreated CP CML CD34+ samples in contrast to the BC CML cell lines 
and transduced murine cells used by other groups.  
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4.6 Potential future work 
There is scope to extend the work produced by this project from cell line, patient 
samples and stem cell data. 
 
4.6.1 Extension of cell line data 
We provided evidence that BCR-ABL+ cell lines have detectable proteasome 
activity and furthermore this activity may vary between BCR-ABL mutations. It 
would be important to establish whether this translates to a subtle difference in 
susceptibility to the apoptotic and antiproliferative effects and levels of detectable 
proteasome activity. This could be assessed with a series of dose-response 
experiments using bortezomib and the 4 BCR-ABL+ Ba/F3 mutants. Confirmed 
differences would imply a biological difference between the cell lines in line with 
current work in this field. 
 
4.6.2 Extension of patient sample data 
All CD34+ samples were taken at diagnosis from patients with CP CML. It would 
be of relevance clinically to establish whether BCR-ABL+ cells taken from patients 
who have failed IM therapy due to IM-resistance of intolerance demonstrate 
comparable sensitivity. Such cell samples are available through a collaborator (F. 
Niccolini) and testing of these forms the basis of a future project.  
 
4.6.3 Extension of stem cell data 
We did not perform functional analysis of the CD34+ CML cells to characterise the 
influence of bortezomib on the ability of cells to form colonies or to persist in long 
term culture. To confirm an effect on the most primitive quiescent population of 
Ph+HSC It is important to establish whether bortezomib (as monotherapy or in 
combination with TKI) influences LTC-IC potential. This could be performed as a 
4-arm experiment comparing untreated CD34+ CML cells with dasatinib and 
bortezomib alone or in combination. Such an experiment would also yield 
additional CFU data, a further measure of proliferation and differentiation. A logical 
extension to LTC-IC would involve transplantation of treated and untreated 
Ph+HSC into immune compromised mice. Such work has been performed by 
Guzman et al. where normal (cord blood) and AML CD34+38- cells were treated 
with a combination of idarubicin and MG132 prior to transplantation into 
NOD/SCID mice. Engraftment was significantly impaired in the treated AML 
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population when compared to control indicating a selective effect of this 
combination on the disease HSC (7).  
 
Functional HSC assays may also characterise any affect of bortezomib on the 
promyelocytic leukaemia (PML) gene. PML is a tumour suppressor that controls 
apoptosis, proliferation, senescence and is involved in neoangiogenesis. It is 
highly expressed in the normal human HSC and is required for HSC maintenance. 
In Ph+HSC PML is highly expressed and through experiments by which PML 
knockdown cells were transduced with BCR-ABL it is seen that PML is required for 
maintenance of LTC-IC. Furthermore downregulation of PML is effective for 
eradication of leukaemia initiating cells (204). PML is a target for proteasomal 
breakdown and PI exposure (MG132) of cell lines (HEK) increases PML levels 
(205). It may be speculated that the effect of bortezomib on the primitive 
population may involve an effect on PML. 
 
4.6.4 Future clinical trials 
The data generated from this project has potential clinical translation. As a front-
line therapy bortezomib use may be difficult to support. IM is an effective well 
tolerated oral drug with 7y of clinical trial data supporting its use. Bortezomib 
would be a clinically unproven, is only available as an intra-venous infusion and 
though relatively well tolerated, has potential toxicities which may be considered 
unacceptable when compared to IM. It is likely that an appropriate role for 
bortezomib would be for those resistant to or intolerant of current treatment, or as 
a combination therapy with TKI. We have generated data that suggests that 
bortezomib targets the primitive Ph+HSC population and so would be expected in 
vivo to reduce MRD to undetectable levels – though clearly in vivo supportive data 
would be required prior to use in patients, for example through transplantation of 
NOD/SCID mice with treated cells. The combination data of dasatinib and 
bortezomib are of particular interest. These drugs used together as front-line 
therapy may enable a significant and rapid reduction of disease burden with a 
presumed associated improved outcome – as shown for those in the IRIS trial who 
had a relatively rapid response to IM. An alternative strategy would be to pursue 
the use of bortezomib in those with TKI-resistance, in particular those with the 
T315I mutation. A combination of bortezomib and dasatinib in this group may 
enable control of T315I and prevent selection for other TKI-sensitive mutations. 
New PI are under development with successful application in clinical trials 
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involving patients with mantle cell lymphoma or multiple myeloma. Of these 
Carfilzomib is of particular interest as it is reported to have similar CT-L inhibitory 
activity to bortezomib, though with fewer “off-target” effects and so reduced 
unwanted toxicity (200). It would therefore be of particular interest to assess this 
drug in vitro as bortezomib has been assessed here.  
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5 CONCLUSIONS 
 
CML is treated effectively with TKI, however two key problems remain - the 
insensitivity of CM HSC to TKI and the emergence of TKI-resistant BCR-ABL 
mutations. BCR-ABL activity is associated with increased proteasome activity and 
PI are cytotoxic against CML cell lines. We demonstrate that bortezomib is 
antiproliferative and induces apoptosis in CD34+ cells taken at diagnosis from 
patients with CP CML cells, with an LD50 below concentrations achieved in vivo. 
We also demonstrate for the first time that CD34+38- CML cells, representing the 
TKI-insensitive primitive HSC, are similarly susceptible. Bortezomib is associated 
with inhibition of proteasome activity, however that of BCR-ABL appears 
unaffected. Significant synergy is seen when bortezomib and dasatinib are used in 
combination. We also demonstrate that bortezomib is effective in inhibiting 
proteasome activity and inducing apoptosis in cell lines expressing BCR-ABL 
mutations, including T315I. Therefore we believe that bortezomib offers a potential 
therapeutic option in CML by targeting both TKI-insensitive stem cells and TKI-
resistant BCR-ABL mutations. 
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